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A single-blind randomised controlled trial investigating the effect of remote ischaemic 
conditioning on clinical outcomes in patients with acute myocardial infarction: The 
CONDI-2/ERIC-PPCI trial.  
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CONSORT 2010 checklist of information to include when reporting a randomised trial 
 
Section/Topic 
Item 
No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for 
abstracts) 
3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 4 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons NA 
Participants 4a Eligibility criteria for participants 5 
4b Settings and locations where the data were collected 4 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
5 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were 
assessed 
6 
6b Any changes to trial outcomes after the trial commenced, with reasons NA 
Sample size 7a How sample size was determined 6 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
 Sequence generation 8a Method used to generate the random allocation sequence 5 
8b Type of randomisation; details of any restriction (such as blocking and block size) 5 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
5 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
5 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
5 
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11b If relevant, description of the similarity of interventions NA 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 6 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 6 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
19 
13b For each group, losses and exclusions after randomisation, together with reasons 19 
Recruitment 14a Dates defining the periods of recruitment and follow-up 7 
14b Why the trial ended or was stopped NA 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 15 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by 
original assigned groups 
17 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision 
(such as 95% confidence interval) 
17 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 17 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-
specified from exploratory 
24 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 8 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 11 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 9 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 9 
Other information 
 
Registration 23 Registration number and name of trial registry 3 
Protocol 24 Where the full trial protocol can be accessed, if available 5 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 7 
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CONSORT 2010 checklist for abstractof information to include  
Item Description Reported on 
line number 
Title  Identification of the study as randomized 1 
Authors * Contact details for the corresponding author NA 
Trial design Description of the trial design (e.g. parallel, cluster, non-
inferiority) 
3 
Methods   
  Participants Eligibility criteria for participants and the settings where 
the data were collected 
3 
  Interventions Interventions intended for each group 3 
  Objective Specific objective or hypothesis 3 
  Outcome Clearly defined primary outcome for this report 3 
  Randomization How participants were allocated to interventions 3 
  Blinding 
(masking) 
Whether or not participants, care givers, and those 
assessing the outcomes were blinded to group 
assignment 
3 
Results   
  Numbers 
randomized 
Number of participants randomized to each group 3 
  Recruitment Trial status 3 
  Numbers 
analysed 
Number of participants analysed in each group 3 
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
3 
  Harms Important adverse events or side effects 3 
Conclusions General interpretation of the results 3 
Trial registration Registration number and name of trial register 3 
Funding Source of funding 3 
 
*this item is specific to conference abstracts 
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CONSORT checklist for Harms 
 
 
Reported 
on page 
 
 
 
1 
 
 
NA 
 
 
 
 
 
Protocol 
page 23 
 
 
 
 
 
 
 
 
 
Protocol 
page 23 
 
 
9 
 
 
9 
 
 
 
 
 
 
NA 
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Recruitment by site in CONDI-2 trial 
 
Inclusion site Number of patients included 
Aarhus University Hospital 1354 
Rigshospitalet, Copenhagen 287 
Odense University Hospital 104 
Aalborg University Hospital 301 
Clinical Centre of Serbia, Belgrade 206 
Hospital Universitario de Cabueñes, Asturias 307 
 
 
 
 Recruitment by site in ERIC-PPCI trial 
 
Inclusion site Number of patients included 
Cumberland Infirmary, Carlisle 128 
Barts Heart Centre 68 
Basildon University Hospital 60 
John Radcliffe Hospital 146 
Northern General Hospital 63 
Leeds General Infirmary 420 
King's College Hospital 132 
Manchester Royal Infirmary 97 
Norfolk and Norwich 105 
New Cross, Wolverhampton 79 
Royal Free Hospital 149 
St Thomas' Hospital 50 
Lister Hospital, Stevenage 130 
Queen Alexandra, Portsmouth 384 
Lincoln County 71 
Papworth Hospital 50 
Victoria Hospital, Blackpool 118 
Royal Bournemouth 93 
Royal Sussex, Brighton 93 
Coventry University Hospital 30 
Royal Stoke University Hospital 107 
Birmingham Heartlands 56 
Kettering General 66 
Hammersmith Hospital 22 
Bristol Royal Infirmary 43 
William Harvey Hospital 30 
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 Rajesh Kharbanda (Co-Principal Investigator, John Radcliffe Hospital, UK) 
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 Rod Stables (Liverpool Heart and Chest Hospital, UK) 
 Simon Redwood (St Thomas’ Hospital, UK) 
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 Rosemary Knight (Senior Trials Manager, London School of Hygiene and Tropical Medicine Clinical 
Trials Unit) 
 Alexander Perkins (Trials Manager, London School of Hygiene and Tropical Medicine Clinical Trials Unit) 
 Richard Evans (Senior Trials Manager, London School of Hygiene and Tropical Medicine Clinical Trials 
Unit) 
 Matthew Dodd (Medical Statistician, London School of Hygiene and Tropical Medicine Clinical Trials 
Unit) 
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 Alan Berry (Previous PPCI patient) 
 
CONDI-2 Trial Steering Committee 
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CONDI-2 Data Monitoring Committee 
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SUPPLEMENTARY METHODS 
Definition of cardiac death: All deaths for which there was no clinical or post-mortem evidence of non-cardiac 
etiology.  
 
Definition of hospitalization for heart failure: Hospitalization for heart failure included heart failure both 
during the index hospitalization and re-hospitalization for heart failure. Hospitalization was defined as treatment 
occurring during a hospital admission. Heart failure was judged to be present based on at least one of the 
following symptoms and signs: new or worsening dyspnea, orthopnea, paroxysmal nocturnal dyspnea, 
increasing fatigue/worsening exercise tolerance, echocardiography (EF<45%), new pulmonary oedema seen on 
chest X-ray in the absence of a non-cardiac cause, crepitations believed to be due to pulmonary edema, and use 
of loop diuretics to treat presumed pulmonary congestion1.   
 
Definition of stroke: Stroke was defined as a focal central neurological deficit lasting >24 hours that resulted in 
irreversible brain damage or body impairment. Stroke was classified as follows: infarction, haemorrhagic stroke, 
and transient ischaemic attack, verified by CT or MRI.  
 
Definition of reinfarction: Reinfarction was defined as an acute MI that occurred within the 1-year follow-up 
period according to the universal definition of myocardial infarction2.  Reinfarction within the first 48 hours 
following the index STEMI was considered procedure-related and not classified as part of the secondary end 
point. 
 
Definition of coronary revascularisation: Revascularisation was defined as symptom-driven coronary 
revascularisation by PCI or CABG following the index PPCI, excluding staged PPCI. 
 
Clinicaltrials.gov registration 
The CONDI-2/ERIC-PPCI trial is a planned pre-specified collaboration between CONDI-2 (recruiting patients 
in Denmark, Spain and Serbia) and ERIC-PPCI (recruiting patients in UK) and is registered at clinicaltrials.gov 
NCT02342522. The CONDI-2 trial was set-up first and recruited their first patient on 6th Nov 2013, having 
registered their clinicaltrials.gov entry on 18th May, 2013 (NCT01857414). The ERIC-PPCI trial 
clinicaltrials.gov entry was set-up 21st January 2015 (NCT02342522) and the first ERIC-PPCI patient was 
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recruited on 15th December 2015. We then merged the 2 clinicaltrials.gov entries to the ERIC-PPCI entry 
NCT02342522 as advised by the clinicaltrials.gov team. This explains why the date of registration shows as 21st 
Jan 2015 and date first patient recruited shows 6th Nov 2013. 
 
Troponin T Substudy 
MI size was quantified as the 48 hour AUC serum level of high-sensitive Troponin-T (hsTropT). From each 
patient of the ERIC-PPCI component study, a single blood sample was taken at each of the 5 time-points (0, 6, 
12, 24 and 48 hours following PPCI procedure). From each patient of the CONDI-2 component study, a single 
blood sample was taken at each of the 4 time-points (0, 6-8, 24 and 48 hours following PPCI procedure). 
Quantitative serum hsTropT measurement was performed using a one-step immunoassay based on 
electrochemiluminescence technology (Elecsys 2010, Roche, Switzerland). The reference range will be ≤14 
ng/L (14 ng/L is the 99th centile of reference population with cardiovascular risk of <10%).  
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SUPPLEMENTARY FIGURES 
 
 
Figure S1. Consort Diagram of the CONDI-2 Trial. 
CONSORT Diagram, CONDI2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysed under intention to treat (n=1,272) 
 
Lost to follow-up (n=0) 
 
Allocated to control arm (n=1,306) 
 Included on arrival at hospital, n=1,272 
 Excluded on arrival to hospital, n=34 
o After verbal consent, refused to give written 
consent, n=13 
o Died before written consent obtained, n=2 
o Language barrier, n=4 
o Mental impairment, n=5 
o Randomised in error, n=10 
Lost to follow-up (n=0) 
Allocated to RIC (n=1,307) 
 Included on arrival at hospital, n=1,278 
 Excluded on arrival to hospital, n=28 
o After verbal assent, refused written consent, 
n=13 
o Died before written consent obtained, n=2 
o Language barrier, n=5 
o Mental impairment, n=2 
o Randomised in error, n=7 
Analysed under intention to treat (n=1,278) 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=2613) 
Enrollment 
Analysed under per-protocol (n=1,062) 
 Excluded from per-protocol analysis (n=210) 
o No STEMI, n=147 
o No PPCI performed, n=49 
o Cross-over, n=14 
 
Analysed under per-protocol (n=984) 
 Excluded from per-protocol analysis (n=294) 
o No STEMI, n=145 
o No PPCI performed, n=54 
o Did not receive intervention as 
specified in protocol, n=95 
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Figure S2 
(a) Cumulative Incidence of Cardiac death or HHF in the CONDI-2/ERIC-PPCI Trial  at 12 months (PP 
Analysis). 
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 (b) Cumulative Incidence of Cardiac death or HHF in the CONDI-2 Trial at 12 months (ITT Analysis). 
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(c) Cumulative Incidence of Cardiac Death in the CONDI-2 Trial at 12 months (ITT Analysis). 
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(d) Cumulative Incidence of HHF in the CONDI-2 Trial at 12 months (ITT Analysis). 
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Figure S3. 
(a) Cumulative Incidence of Cardiac Death or HHF in the CONDI-2 Trial at 12 Months (PP Analysis). 
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(b) Cumulative Incidence of Cardiac Death in the CONDI-2 Trial at 12 Months (PP Analysis). 
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(c) Cumulative Incidence of HHF in the CONDI-2 Trial at 12 Months (PP Analysis). 
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Figure S4. Consort Diagram of the ERIC-PPCI Trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Full screening log data were not available as not all sites were able to collect screening logs given the 
emergency context of patient enrolment and randomization. 
**ERIC-PPCI had approval from the UK Confidentiality Group (CAG) to collect data on patients how died 
before consent could be obtained. 
 
Analysed under intention to treat (n=1,297) 
 
Lost to follow-up (n=98) 
o Patient refused consent for follow-up, 
n=69 
o Patient withdrew, n=2 
o Language barrier, n=3 
o Patient lacked capacity to consent, 
n=7 
o Patient discharged prior to consent, 
n=13 
o Randomised in error, n=2 
o Clinical decision to withdraw, n=2 
o Patient died prior to consent, n/a** 
Allocated to receive Control (n=1,395) 
 
Lost to follow-up (n=125) 
o Patient refused consent for follow-up, 
n=84 
o Patient withdrew, n=3 
o Language barrier, n=6 
o Patient lacked capacity to consent, 
n=6 
o Patient discharged prior to consent, 
n=19 
o Randomised in error, n=2 
o Clinical decision to withdraw, n=5 
o Patient died prior to consent, n/a** 
o  
 
Allocated to receive RIC (n=1,393) 
Analysed under intention to treat (n=1,268) 
 
Allocation 
Analysis 
Follow-Up 
Analysed under per-protocol (n=1,143) 
 Excluded from per-protocol analysis (n=154) 
o No STEMI, n=72 
o No PPCI performed, n=37 
o Did not receive Control as specified in 
protocol, n=45 
Analysed under per-protocol (n=1,024) 
 Excluded from per-protocol analysis (n=244) 
o No STEMI, n=65 
o No PPCI performed, n=26 
o Did not receive RIC as specified in 
protocol, n=153 
Randomised (n=2788) 
Enrollment 
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Figure S5. 
(a) Cumulative Incidence of Cardiac Death or HHF in the ERIC-PPCI Trial at 12 Months (ITT Analysis). 
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(b) Cumulative Incidence of Cardiac Death in the ERIC-PPCI Trial at 12 Months (ITT Analysis). 
 
  
33 
 
(c) Cumulative Incidence of HHF in the ERIC-PPCI Trial at 12 months (ITT Analysis). 
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Figure S6. 
(a) Cumulative Incidence of Cardiac Death or HHF in the ERIC-PPCI Trial at 12 Months (PP Analysis). 
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(b) Cumulative Incidence of Cardiac Death in the ERIC-PPCI Trial at 12 Months (PP Analysis). 
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(c) Cumulative Incidence of HHF in the ERIC-PPCI Trial at 12 Months (PP Analysis). 
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Table S1a. Baseline Characteristics of Patients and PPCI Procedure Details in the CONDI-2/ERIC-PPCI 
Trial (ITT Analysis).  
          
 
Control RIC 
  (n=2569) (n=2546) 
Demographics 
    Age (years), mean (SD) 63.1 (12.2) 63.9 (12.1) 
Missing, n 20 
 
22 
 Female, n (%) 576 (22.4) 611 (24.0) 
Missing, n 0 
 
0 
 Body mass index (BMI; kg/m2), mean (SD) 27.5 (4.7) 27.5 (4.9) 
Missing, n 129 
 
120 
 Current smokers, n (%) 1015 (40.9) 993 (40.5) 
Missing, n 86 
 
97 
 
     Comorbidity, n (%) 
    Hypertension 1020 (40.1) 1100 (43.7) 
Missing, n 25 
 
28 
 Previous acute myocardial infarction (MI) 253 (9.9) 265 (10.5) 
Missing, n 16 
 
16 
 Hypercholesterolemia 682 (27.2) 696 (28.0) 
Missing, n 66 
 
56 
 Medically treated diabetes 265 (10.4) 302 (11.9) 
Missing, n 12 
 
12 
 Family history of ischaemic heart disease (IHD) 819 (34.3) 853 (36.5) 
Not known, n 182 
 
209 
 
     Medications at admission for PPCI, n (%) 
    Sulphonylurea 62 (2.5) 61 (2.4) 
Missing, n 50 
 
50 
 Metformin 196 (7.8) 221 (8.8) 
Missing, n 51 
 
47 
 Insulin 74 (2.9) 81 (3.2) 
Missing, n 21 
 
13 
 Clopidogrel 85 (3.3) 98 (3.9) 
Missing, n 21 
 
18 
 Ticagrelor 52 (2.0) 62 (2.5) 
Missing, n 20 
 
19 
 Prasugrel 4 (0.2) 3 (0.1) 
Missing, n 23 
 
18 
 Statins 652 (25.6) 665 (26.3) 
Missing, n 22 
 
20 
 Aspirin 456 (17.9) 665 (19.2) 
Missing, n 21 
 
18 
 Beta-blockers 384 (15.1) 407 (16.1) 
38 
 
Missing, n 30  21  
ACE inhibitors/Angiotensin receptor blockers 456 (17.9) 466 (18.5) 
                Missing, n           28            21  
BP and Killip class at randomisation 
    Systolic blood pressure (mmHg), mean (SD) 131 (24) 131 (24) 
Missing, n 79 
 
78 
 Diastolic blood pressure (mmHg), mean (SD) 77 (15) 76 (15) 
Missing, n 83 
 
80 
 Killip class, n (%) 
    Class I 2462 (95.9) 2435 (95.6) 
Class II 75 (2.9) 75 (2.9) 
Class III 14 (0.5) 11 (0.4) 
Class IV (including cardiogenic shock) 17 (0.7) 25 (1.0) 
Missing, n 1 
 
0 
 
     RIC procedure 
    RIC procedure started, n (%) - 
 
2496 (98.0) 
Missing, n - 
 
0 
 Number of complete RIC cycles administered, n (%) 
    1 - 
 
37 (1.6) 
2 - 
 
40 (1.8) 
3 - 
 
142 (6.3) 
4 - 
 
2027 (90.2) 
Missing, n - 
 
250 
 
     PPCI procedure 
    PPCI completed, n (%) 2258 (87.9) 2227 (87.5) 
TIMI flow grade at admission, n (%) 
    TIMI 0 1513 (67.9) 1478 (67.1) 
TIMI 1 154 (6.9) 145 (6.6) 
TIMI 2 218 (9.8) 225 (10.2) 
TIMI 3 342 (15.4) 355 (16.1) 
Missing, n 31 
 
24 
 
Symptom to balloon time (min), median (IQR) 177 
(128 to 
279) 178 
(130 to 
278) 
Missing, n 339 
 
361 
 First medical contact to balloon time (min), median (IQR) 102 (82 to 126) 103 (83 to 128) 
Missing, n 356 
 
385 
 Infarct-related coronary artery, n (%) 
    Left anterior descending 974 (43.1) 911 (40.9) 
Circumflex 297 (13.2) 298 (13.4) 
Right coronary 985 (43.6) 1014 (45.6) 
Other 2 (0.1) 3 (0.1) 
Missing, n 0 
 
1 
 Vessels with clinically significant disease, n (%) 
    0 1 (0.0) 2 (0.1) 
39 
 
1 1314 (58.2) 1274 (57.2) 
2 659 (29.2) 641 (28.8) 
3 284 (12.6) 310 (13.9) 
Missing, n 0 
 
0 
 Stenting of culprit lesion by PPCI, n (%) 2104 (93.2) 2080 (93.4) 
Missing, n 0 
 
1 
 Supplementary staged PCI, n (%) 291 (12.9) 261 (11.7) 
Supplementary staged CABG, n (%) 52 (2.3) 62 (2.8) 
TIMI flow grade after procedure, n (%) 
    TIMI 0 27 (1.2) 26 (1.2) 
TIMI 1 20 (0.9) 9 (0.4) 
TIMI 2 112 (5.0) 86 (3.9) 
TIMI 3 2064 (92.8) 2079 (94.5) 
Missing, n 35 
 
27 
 
     Medications administered in relation to PPCI, n (%) 
    Opioids* 549 (52.1) 522 (50.2) 
Missing, n 1204 
 
1187 
 Heparin 1904 (84.4) 1893 (85.1) 
Missing, n 3 
 
3 
 Aspirin 2147 (95.2) 2129 (95.9) 
Missing, n 3 
 
6 
 Clopidogrel 610 (27.0) 573 (25.7) 
Missing, n 2 
 
1 
 Ticagrelor 1551 (68.7) 1554 (69.8) 
Missing, n 1 
 
0 
 Prasugrel 103 (4.6) 97 (4.4) 
Missing, n 2 
 
1 
 Nitrates 1758 (79.1) 1693 (77.5) 
Missing, n 36 
 
42 
 Glycoprotein IIb/IIIa inhibitor 450 (20.0) 404 (18.2) 
Missing, n 8 
 
4 
 Bivalirudin 505 (22.4) 489 (22.0) 
Missing, n 8 
 
3 
 Cangrelor* 134 (12.3) 127 (11.7) 
Missing, n 1170 
 
1142 
           
Abbreviations: RIC = remote ischemic conditioning; SD = standard deviation; IQR = interquartile range; BMI = 
body mass index; MI = myocardial infarction; IHD = ischemic heart disease; PPCI = primary percutaneous 
coronary intervention; BP = blood pressure; CABG = coronary artery bypass graft surgery  
*Opioids and cangrelor data collected only in CONDI-2. 
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Table S2. Subgroup Analyses for the CONDI-2/ERIC-PPCI Trial (ITT Analysis). 
 
 Control 
(n=2569) 
RIC 
(n=2546) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Age (years), n (%)        
    <55 24 (3.5) 22 (3.5) 1.00 (0.56 to 1.78)  
    55-<65 40 (5.3) 48 (7.0) 1.33 (0.87 to 2.02)  
    65-<75 58 (9.4) 65 (9.0) 0.97 (0.68 to 1.38)  
    ≥75 79 (16.9) 85 (17.9) 1.05 (0.77 to 1.43) 0.70 
Medically treated diabetes, n (%)        
    No 179 (7.9) 193 (8.7) 1.11 (0.91 to 1.36)  
    Yes 38 (14.6) 43 (14.5) 0.98 (0.63 to 1.51) 0.60 
TIMI flow grade at admission, n (%)        
    TIMI 0-1 156 (9.2) 169 (10.3) 1.11 (0.89 to 1.38)  
    TIMI 2-3 36 (5.7) 42 (6.5) 1.14 (0.73 to 1.78) 0.92 
Infarct location, n (%)        
    Left anterior descending 132 (13.3) 147 (15.7) 1.21 (0.96 to 1.53)  
    Other 65 (5.0) 66 (4.9) 0.98 (0.70 to 1.39) 0.33 
First medical contact to balloon time (min), n (%)        
    <90 46 (6.2) 56 (7.7) 1.24 (0.84 to 1.84)  
    90-<120 63 (7.9) 60 (8.2) 1.01 (0.71 to 1.44)  
    120-≤720 73 (10.9) 75 (10.8) 1.01 (0.73 to 1.39) 0.67 
        
Exploratory analyses        
Timing of intervention, n (%)        
    In ambulance (n=2,290) 113 (10.0) 112 (9.8) 0.98 (0.76 to 1.28)  
    On arrival at hospital (n=2,825) 107 (7.5) 127 (9.1) 1.22 (0.95 to 1.58) 0.24 
Timing of intervention in relation to reperfusion, n 
(%)        
    ≤4 cycles of RIC prior to reperfusion (n=1,030) 220 (8.6) 82 (8.0) 1.07 (0.81 to 1.41) 0.64 
    4 cycles of RIC prior to reperfusion (n=1,079) 220 (8.6) 106 (9.9) 1.03 (0.80 to 1.31) 0.84 
Gender, n (%)        
    Male 152 (7.7) 172 (8.9) 1.17 (0.94 to 1.46)  
    Female 68 (11.9) 67 (11.1) 0.92 (0.66 to 1.29) 0.24 
Smoking status, n (%)        
    Current smoker 64 (6.3) 78 (7.9) 1.26 (0.90 to 1.75)  
    Ex-smoker 70 (9.4) 65 (8.7) 0.92 (0.65 to 1.28)  
    Never smoked 73 (10.2) 80 (11.4) 1.12 (0.81 to 1.54) 0.42 
BMI (kg/m2), n (%)        
    <25 64 (8.2) 74 (9.7) 1.18 (0.85 to 1.65)  
    ≥25 141 (8.6) 148 (9.0) 1.05 (0.83 to 1.32) 0.56 
Symptom to balloon time (min), n (%)        
    <150 46 (5.4) 62 (7.9) 1.47 (1.01 to 2.16)  
    150-<240 61 (9.4) 59 (8.3) 0.89 (0.62 to 1.27)  
    240-≤720 66 (10.0) 65 (10.1) 1.01 (0.72 to 1.42) 0.15 
Hypertension, n (%)        
    No 110 (7.2) 108 (7.7) 1.06 (0.81 to 1.38)  
    Yes 105 (10.4) 125 (11.5) 1.10 (0.85 to 1.43) 0.82 
Beta-blockers, n (%)        
    No 169 (7.9) 190 (9.0) 1.15 (0.93 to 1.41)  
    Yes 40 (10.5) 43 (10.7) 1.00 (0.65 to 1.54) 0.58 
ACE-inhibitors, n (%)        
    No 164 (7.9) 181 (8.9) 1.12 (0.91 to 1.38)  
    Yes 45 (10.0) 52 (11.2) 1.13 (0.76 to 1.69) 0.95 
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 Control 
(n=2569) 
RIC 
(n=2546) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
 
Angiotensin II receptor blockers, n (%) 
    No 182 (8.0) 201 (9.1) 1.15 (0.94 to 1.40)  
    Yes 28 (11.3) 32 (10.6) 0.90 (0.54 to 1.49) 0.37 
Statins, n (%)        
    No 148 (7.8) 169 (9.1) 1.17 (0.94 to 1.46)  
    Yes 64 (9.9) 64 (9.7) 0.97 (0.69 to 1.38) 0.39 
Metformin, n (%)        
    No 184 (8.0) 201 (8.9) 1.12 (0.91 to 1.36)  
    Yes 20 (10.3) 24 (11.0) 1.06 (0.58 to 1.91) 0.86 
Sulphonylurea, n (%)        
    No 199 (8.1) 218 (9.0) 1.11 (0.91 to 1.34)  
    Yes 5 (8.1) 7 (11.8) 1.39 (0.44 to 4.38) 0.70 
Insulin, n (%)        
    No 198 (8.1) 213 (8.7) 1.09 (0.90 to 1.32)  
    Yes 15 (20.5) 21 (26.2) 1.30 (0.67 to 2.52) 0.61 
Ticagrelor, n (%)        
    No 84 (10.4) 91 (11.7) 1.12 (0.84 to 1.51)  
    Yes 124 (7.6) 131 (8.0) 1.06 (00.83 to 1.35) 0.75 
 
The Table presents Kaplan-Meier estimates of the n (%) experiencing hospitalization for heart failure or 
cardiovascular death within 12 months.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval 
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Table S3. Baseline Characteristics of Patients and PPCI Procedure Details in the CONDI-2 Trial (ITT 
analysis).  
          
 
Control RIC 
  (n=1272) (n=1278) 
Demographics 
    Age (years), mean (SD) 62.9 (12.1) 63.6 (12.1) 
Missing, n 0 
 
0 
 Female, n (%) 294 (23.1) 322 (25.2) 
Missing, n 0 
 
0 
 Body mass index (BMI; kg/m2), mean (SD) 27.3 (4.5) 27.4 (4.8) 
Missing, n 56 
 
46 
 Current smokers, n (%) 571 (45.7) 549 (44.1) 
Missing, n 22 
 
32 
 
     Comorbidity, n (%) 
    Hypertension 501 (39.4) 552 (43.2) 
Missing, n 2 
 
1 
 Previous acute myocardial infarction (MI) 141 (11.1) 132 (10.3) 
Missing, n 2 
 
2 
 Hypercholesterolemia 314 (24.7) 317 (24.8) 
Missing, n 3 
 
2 
 Medically treated diabetes 124 (9.8) 156 (12.2) 
Missing, n 1 
 
1 
 Family history of ischaemic heart disease (IHD) 389 (31.9) 407 (33.2) 
Not known, n 53 
 
51 
 
     Medications at admission for PPCI, n (%) 
    Sulphonylurea 18 (1.5) 20 (1.6) 
Missing, n 34 
 
38 
 Metformin 83 (6.7) 106 (8.5) 
Missing, n 34 
 
37 
 Insulin 33 (2.6) 43 (3.4) 
Missing, n 3 
 
2 
 Clopidogrel 40 (3.2) 37 (2.9) 
Missing, n 3 
 
4 
 Ticagrelor 5 (0.4) 18 (1.4) 
Missing, n 3 
 
4 
 Prasugrel 1 (0.1) 0 (0.0) 
Missing, n 3 
 
4 
 Statins 300 (23.7) 310 (24.4) 
Missing, n 4 
 
5 
 Aspirin 222 (17.5) 225 (17.7) 
Missing, n 4 
 
4 
 Beta-blockers 187 (14.8) 207 (16.2) 
43 
 
Missing, n 9  4  
ACE inhibitors/Angiotensin receptor blockers 204 (16.2) 195 (15.3) 
Missing, n 9  4  
BP and Killip class at randomisation 
    Systolic blood pressure (mmHg), mean (SD) 129 (24) 130 (25) 
              Missing, n 11 
 
44 
 Diastolic blood pressure (mmHg), mean (SD) 74 (14) 74 (15) 
Missing, n 13 
 
44 
 Killip class, n (%) 
    Class I 1193 (93.9) 1198 (93.7) 
Class II 54 (4.2) 56 (4.4) 
Class III 13 (1.0) 8 (0.6) 
Class IV (including cardiogenic shock) 11 (0.9) 16 (1.3) 
Missing, n 1 
 
0 
 
     RIC procedure 
    RIC procedure started, n (%) - 
 
1245 (97.4) 
Number of complete RIC cycles administered, n (%) 
    1 - 
 
4 (0.4) 
2 - 
 
12 (1.2) 
3 - 
 
62 (6.1) 
4 - 
 
945 (92.4) 
Missing, n - 
 
222 
 
     PPCI procedure 
    PPCI completed, n (%) 1090 (85.7) 1085 (84.9) 
TIMI flow grade at admission, n (%) 
    TIMI 0 638 (58.9) 638 (59.0) 
TIMI 1 78 (7.2) 58 (5.4) 
TIMI 2 135 (12.5) 136 (12.6) 
TIMI 3 233 (21.5) 249 (23.0) 
Missing, n 6 
 
4 
 
Symptom to balloon time (min), median (IQR) 173 
(123 to 
280) 172 
(123 to 
276) 
Missing, n 185 
 
200 
 First medical contact to balloon time (min), median (IQR) 94 (76 to 119) 95 (76 to 118) 
Missing, n 184 
 
201 
 Infarct-related coronary artery, n (%) 
    Left anterior descending 481 (44.1) 434 (40.0) 
Circumflex 153 (14.0) 152 (14.0) 
Right coronary 456 (41.8) 499 (46.0) 
Missing, n 0 
 
0 
 Vessels with clinically significant disease, n (%) 
    0 0 (0.0) 0 (0.0) 
1 654 (60.0) 651 (60.0) 
2 305 (28.0) 278 (25.6) 
44 
 
3 131 (12.0) 156 (14.4) 
Missing, n 0 
 
0 
 Stenting of culprit lesion by PPCI, n (%) 990 (90.8) 984 (90.7) 
Missing, n 0 
 
0 
 Supplementary staged PCI, n (%) 189 (17.3) 164 (15.1) 
Supplementary staged CABG, n (%) 36 (3.3) 47 (4.3) 
TIMI flow grade after procedure, n (%) 
    TIMI 0 13 (1.2) 11 (1.0) 
TIMI 1 13 (1.2) 2 (0.2) 
TIMI 2 49 (4.5) 33 (3.1) 
TIMI 3 1010 (93.1) 1035 (95.7) 
Missing, n 5 
 
4 
 
     Medications administered in relation to PPCI, n (%) 
    Opioids 549 (52.1) 522 (50.2) 
Missing, n 36 
 
45 
 Heparin 824 (75.7) 822 (76.0) 
Missing, n 2 
 
3 
 Aspirin 1072 (98.4) 1073 (99.2) 
Missing, n 1 
 
3 
 Clopidogrel 230 (21.1) 225 (20.7) 
Missing, n 0 
 
0 
 Ticagrelor 760 (69.7) 761 (70.1) 
Missing, n 0 
 
0 
 Prasugrel 1 (0.1) 1 (0.1) 
Missing, n 0 
 
0 
 Nitrates 789 (74.8) 744 (71.3) 
Missing, n 35 
 
42 
 Glycoprotein IIb/IIIa inhibitor 143 (13.2) 130 (12.0) 
Missing, n 7 
 
4 
 Bivalirudin 442 (40.8) 426 (39.4) 
Missing, n 7 
 
3 
 Cangrelor 134 (12.3) 127 (11.7) 
Missing, n 2 
 
0 
           
Abbreviations: RIC = remote ischemic conditioning; SD = standard deviation; IQR = interquartile range; BMI = 
body mass index; MI = myocardial infarction; IHD = ischemic heart disease; PPCI = primary percutaneous 
coronary intervention; BP = blood pressure; CABG = coronary artery bypass graft surgery  
*Opioids and cangrelor data collected only in CONDI-2. 
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Table S4. Primary and Secondary Outcomes in the CONDI-2 Trial (ITT Analysis). 
 
 Control 
(n=1272) 
RIC 
(n=1278) 
Treatment effect, p-value 
 RIC vs. Control 
 (95% CI) 
Primary outcome, n (%)        
Combined HHF and Cardiac death within 12 months 129 (10.3) 130 (10.3) 1.00 (0.79 to 1.28) 0.98 
    Cardiac death within 12 months 31 (2.5) 41 (3.3) 1.32 (0.83 to 2.11) 0.24 
    HHF within 12 months 118 (9.4) 114 (9.0) 0.96 (0.74 to 1.25) 0.77 
        
Secondary outcomes, n (%)        
MACCE within 12 months 109 (8.7) 111 (8.8) 1.02 (0.78 to 1.32) 0.90 
    All-cause mortality within 12 months 48 (3.8) 62 (4.9) 1.29 (0.89 to 1.88) 0.18 
    Reinfarction within 12 months 27 (2.2) 22 (1.8) 0.81 (0.46 to 1.43) 0.47 
    Unplanned revascularisation within 12 months 29 (2.4) 26 (2.1) 0.90 (0.53 to 1.52) 0.69 
    Stroke within 12 months 15 (1.2) 14 (1.1) 0.94 (0.45 to 1.94) 0.86 
        
Combined HHF and cardiac death within 30 days 103 (8.2) 103 (8.1) 0.99 (0.76 to 1.31) 0.96 
    Cardiac death within 30 days 20 (1.6) 26 (2.1) 1.29 (0.72 to 2.32) 0.39 
    HHF within 12 months 103 (8.2) 99 (7.8) 0.96 (0.73 to 1.26) 0.76 
        
MACCE within 30 days 49 (3.9) 48 (3.8) 0.98 (0.65 to 1.45) 0.90 
    All-cause mortality within 30 days 23 (1.8) 26 (2.1) 1.12 (0.64 to 1.97) 0.68 
    Reinfarction within 30 days 11 (0.9) 7 (0.6) 0.63 (0.25 to 1.63) 0.34 
    Unplanned revascularisation within 30 days 11 (0.9) 12 (1.0) 1.09 (0.48 to 2.46) 0.84 
    Stroke within 30 days 4 (0.3) 5 (0.4) 1.25 (0.33 to 4.64) 0.74 
        
ICD implantation within 12 months 6 (0.5) 8 (0.6) 1.33 (0.46 to 3.81) 0.60 
        
Repeat HHF, mean count (SD) 0.11 (0.40) 0.11 (0.38) 0.94 (0.72 to 1.23) 0.66 
Repeat HHF and cardiac death, mean count (SD) 0.14 (0.47) 0.14 (0.47) 1.01 (0.77 to 1.31) 0.96 
 
For time-to-event outcomes, Kaplan-Meier estimates of the n (%) with the outcome at 30 days/12 months are 
presented.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval; HHF = hospitalisation for heart 
failure; MACCE = composite of all-cause mortality, reinfarction, unplanned revascularisation, and stroke; ICD 
= implantable cardioverter-defibrillator; SD = standard deviation 
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Table S5. Subgroup Analyses for the CONDI-2 trial (ITT Analysis). 
 
 Control 
(n=1272) 
RIC 
(n=1278) 
Treatment effect, Interaction 
p-value  RIC vs Control 
 (95% CI) 
Age (years), n (%)        
    <55 16 (4.7) 12 (3.7) 0.78 (0.37 to 1.65)  
    55-<65 26 (6.8) 30 (8.5) 1.26 (0.75 to 2.14)  
    65-<75 38 (12.1) 40 (11.2) 0.92 (0.59 to 1.43)  
    ≥75 49 (22.0) 48 (21.2) 0.94 (0.63 to 1.40) 0.71 
Medically treated diabetes, n (%)        
    No 103 (9.1) 106 (9.5) 1.05 (0.80 to 1.38)  
    Yes 25 (20.7) 24 (15.8) 0.75 (0.43 to 1.31) 0.28 
TIMI flow grade at admission, n (%)        
    TIMI 0-1 89 (12.5) 80 (11.6) 0.92 (0.68 to 1.24)  
    TIMI 2-3 20 (5.5) 27 (7.1) 1.30 (0.73 to 2.32) 0.30 
Infarct location, n (%)        
    Left anterior descending 78 (16.4) 79 (18.4) 1.14 (0.83 to 1.56)  
    Other 32 (5.3) 28 (4.3) 0.81 (0.49 to 1.35) 0.26 
First medical contact to balloon time (min), n (%)        
    <90 39 (8.2) 47 (9.9) 1.22 (0.80 to 1.87)  
    90-<120 35 (10.3) 29 (8.5) 0.81 (0.50 to 1.33)  
    120-≤720 36 (13.6) 30 (12.0) 0.88 (0.54 to 1.42) 0.40 
        
Exploratory analyses        
Gender, n (%)        
    Male 89 (9.2) 94 (9.9) 1.08 (0.81 to 1.45)  
    Female 40 (13.7) 36 (11.4) 0.81 (0.52 to 1.27) 0.29 
Smoking status, n (%)        
    Current smoker 46 (8.1) 52 (9.6) 1.18 (0.80 to 1.76)  
    Ex-smoker 38 (11.0) 36 (9.9) 0.89 (0.57 to 1.41)  
    Never smoked 39 (12.0) 39 (12.0) 1.00 (0.64 to 1.56) 0.65 
BMI (kg/m2), n (%)        
    <25 40 (10.3) 44 (11.3) 1.10 (0.72 to 1.68)  
    ≥25 85 (10.5) 83 (10.0) 0.96 (0.71 to 1.30) 0.61 
Symptom to balloon time (min), n (%)        
    <150 31 (7.0) 35 (8.2) 1.18 (0.73 to 1.92)  
    150-<240 35 (12.1) 27 (8.6) 0.71 (0.43 to 1.17)  
    240-≤720 35 (10.9) 39 (12.4) 1.14 (0.72 to 1.79) 0.28 
Hypertension, n (%)        
    No 63 (8.2) 66 (9.2) 1.12 (0.79 to 1.58)  
    Yes 65 (13.2) 64 (11.8) 0.88 (0.63 to 1.25) 0.34 
Beta-blockers, n (%)        
    No 102 (9.6) 112 (10.6) 1.11 (0.85 to 1.46)  
    Yes 22 (12.0) 17 (8.4) 0.68 (0.36 to 1.28) 0.16 
ACE-inhibitors, n (%)        
    No 99 (9.4) 105 (9.8) 1.05 (0.80 to 1.38)  
    Yes 25 (12.6) 24 (12.4) 0.98 (0.56 to 1.72) 0.84 
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 Control 
(n=1272) 
RIC 
(n=1278) 
Treatment effect, Interaction 
p-value  RIC vs Control 
 (95% CI) 
Angiotensin II receptor blockers, n (%) 
    No 107 (9.6) 109 (10.1) 1.06 (0.81 to 1.39)  
    Yes 17 (12.7) 20 (10.9) 0.83 (0.43 to 1.58) 0.49 
Statins, n (%)        
    No 86 (9.0) 96 (10.1) 1.13 (0.84 to 1.51)  
    Yes 39 (13.3) 33 (10.8) 0.80 (0.51 to 1.28) 0.22 
Metformin, n (%)        
    No 103 (9.0) 108 (9.6) 1.07 (0.82 to 1.40)  
    Yes 14 (17.1) 12 (11.6) 0.66 (0.31 to 1.43) 0.25 
Sulphonylurea, n (%)        
    No 115 (9.5) 118 (9.8) 1.03 (0.79 to 1.33)  
    Yes 2 (11.8) 2 (10.5) 0.86 (0.12 to 6.11) 0.86 
Insulin, n (%)        
    No 118 (9.7) 116 (9.5) 0.98 (0.76 to 1.27)  
    Yes 8 (24.6) 13 (30.6) 1.32 (0.55 to 3.20) 0.53 
Ticagrelor, n (%)        
    No 50 (11.8) 56 (13.2) 1.12 (0.77 to 1.64)  
    Yes 79  (9.5) 74 (8.8) 0.93 (0.68 to 1.28)  0.46 
 
This Table presents Kaplan-Meier estimates of the n (%) experiencing hospitalisation for heart failure or 
cardiovascular death within 12 months.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval 
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Table S6. Baseline characteristics of Patients and PPCI Procedure Details in the CONDI-2 Trial (PP 
Analysis).  
          
 
Control RIC 
  (n=1062) (n=984) 
Demographics 
    Age (years), mean (SD) 63.3 (11.7) 63.9 (11.5) 
Missing, n 20 
 
40 
 Female, n (%) 228 (21.5) 236 (24.0) 
Missing, n 0 
 
0 
 Body mass index (BMI; kg/m2), mean (SD) 27.5 (4.5) 27.5 (4.8) 
Missing, n 49 
 
34 
 Current smokers, n (%) 488 (46.6) 443 (46.0) 
Missing, n 14 
 
22 
 
     Comorbidity, n (%) 
    Hypertension 421 (39.7) 418 (42.5) 
Missing, n 1 
 
1 
 Previous acute myocardial infarction (MI) 117 (11.0) 97 (9.9) 
Missing, n 1 
 
1 
 Hypercholesterolemia 258 (24.3) 235 (23.9) 
Missing, n 2 
 
2 
 Medically treated diabetes 107 (10.1) 121 (12.3) 
Missing, n 0 
 
1 
 Family history of ischaemic heart disease (IHD) 329 (32.2) 317 (33.6) 
Not known, n 39 
 
40 
 
     Medications at admission for PPCI, n (%) 
    Sulphonylurea 18 (1.7) 16 (1.7) 
Missing, n 26 
 
25 
 Metformin 71 (6.9) 88 (9.2) 
Missing, n 26 
 
25 
 Insulin 28 (2.6) 29 (3.0) 
Missing, n 0 
 
1 
 Clopidogrel 34 (3.2) 24 (2.4) 
Missing, n 0 
 
3 
 Ticagrelor 4 (0.4) 11 (1.1) 
Missing, n 0 
 
3 
 Prasugrel 0 (0.0) 0 (0.0) 
Missing, n 0 
 
3 
 Statins 239 (22.5) 220 (22.4) 
Missing, n 1 
 
4 
 Aspirin 173 (16.3) 162 (16.5) 
Missing, n 1 
 
3 
   Beta-blockers 155                   (14.7)    155 (15.8) 
49 
 
Missing, n 6 
 
3 
   ACE inhibitors/Angiotensin receptor blockers 172 (16.3) 146 (14.9) 
Missing, n 6 
 
3 
 BP and Killip class at randomisation 
    Systolic blood pressure (mmHg), mean (SD) 129 (24) 129 (24) 
Missing, n 6 
 
13 
 Diastolic blood pressure (mmHg), mean (SD) 74 (14) 74 (15) 
Missing, n 8 
 
13 
 Killip class, n (%) 
    Class I 999 (94.1) 925 (94.0) 
Class II 47 (4.4) 43 (4.4) 
Class III 9 (0.8) 4 (0.4) 
Class IV (including cardiogenic shock) 7 (0.7) 12 (1.2) 
Missing, n 0 
 
0 
 
     RIC procedure 
    RIC procedure started, n (%) - 
 
984 (100.0) 
Number of complete RIC cycles administered, n (%) 
    1 - 
 
4 (0.4) 
2 - 
 
11 (1.1) 
3 - 
 
59 (6.1) 
4 - 
 
896 (92.4) 
Missing, n - 
 
14 
 
     PPCI procedure 
    PPCI completed, n (%) 1062 (100.0) 984 (100.0) 
TIMI flow grade at admission, n (%) 
    TIMI 0 627 (59.3) 584 (59.5) 
TIMI 1 76 (7.2) 54 (5.5) 
TIMI 2 132 (12.5) 118 (12.0) 
TIMI 3 222 (21.0) 225 (22.9) 
Missing, n 5 
 
3 
 
Symptom to balloon time (min), median (IQR) 172 
(123 to 
277) 175 
(123 to 
276) 
Missing, n 3 
 
6 
 First medical contact to balloon time (min), median (IQR) 94 (76 to 119) 95 (75 to 118) 
Missing, n 2 
 
7 
 Infarct-related coronary artery, n (%) 
    Left anterior descending 468 (44.1) 400 (40.7) 
Circumflex 147 (13.8) 133 (13.5) 
Right coronary 447 (42.1) 451 (45.8) 
Missing, n 0 
 
0 
 Vessels with clinically significant disease, n (%) 
    1 634 (59.7) 593 (60.3) 
2 300 (28.2) 252 (25.6) 
3 128 (12.1) 139 (14.1) 
50 
 
Missing, n 0 
 
0 
 Stenting of culprit lesion by PPCI, n (%) 969 (91.2) 892 (90.7) 
Missing, n 0 
 
0 
 Supplementary staged PCI, n (%) 187 (17.6) 148 (15.0) 
Supplementary staged CABG, n (%) 35 (3.3) 43 (4.4) 
TIMI flow grade after procedure, n (%) 
    TIMI 0 11 (1.0) 10 (1.0) 
TIMI 1 13 (1.2) 2 (0.2) 
TIMI 2 47 (4.4) 31 (3.2) 
TIMI 3 986 (93.3) 938 (95.6) 
Missing, n 5 
 
3 
 
     Medications given in relation to PPCI, n (%) 
    Opioids* 530 (51.6) 461 (48.9) 
Missing, n 35 
 
41 
 Heparin 801 (75.6) 739 (75.3) 
Missing, n 2 
 
3 
 Aspirin 1045 (98.5) 973 (99.2) 
Missing, n 1 
 
3 
 Clopidogrel 227 (21.4) 208 (21.1) 
Missing, n 0 
 
0 
 Ticagrelor 742 (69.9) 686 (69.7) 
Missing, n 0 
 
0 
 Prasugrel 1 (0.1) 1 (0.1) 
Missing, n 0 
 
0 
 Nitrates 767 (74.5) 672 (71.0) 
Missing, n 33 
 
38 
 Glycoprotein IIb/IIIa inhibitor 141 (13.4) 116 (11.8) 
Missing, n 7 
 
4 
 Bivalirudin 436 (41.3) 398 (40.6) 
Missing, n 7 
 
3 
 Cangrelor* 129 (12.2) 113 (11.5) 
Missing, n 2 
 
0 
           
Abbreviations: RIC = remote ischemic conditioning; SD = standard deviation; IQR = interquartile range; BMI = 
body mass index; MI = myocardial infarction; IHD = ischemic heart disease; PPCI = primary percutaneous 
coronary intervention; BP = blood pressure; CABG = coronary artery bypass graft surgery  
*Opioids and cangrelor data collected only in CONDI-2. 
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Table S7. Primary and Secondary Outcomes in the CONDI-2 Trial (PP Analysis). 
 
 Control 
(n=1062) 
RIC 
(n=984) 
Treatment effect, p-value 
 RIC vs Control 
 (95% CI) 
Primary outcome, n (%)        
Combined HHF and cardiac death within 12 months 104 (9.9) 100 (10.3) 1.04 (0.79 to 1.37) 0.78 
    Cardiac death within 12 months 25 (2.4) 28 (2.9) 1.21 (0.71 to 2.08) 0.48 
    HHF within 12 months 95 (9.0) 88 (9.0) 1.00 (0.75 to 1.34) 0.99 
        
Secondary outcomes, n (%)        
MACCE within 12 months 90 (8.6) 82 (8.4) 0.99 (0.73 to 1.33) 0.93 
    All-cause mortality within 12 months 36 (3.4) 44 (4.5) 1.33 (0.85 to 2.06) 0.21 
    Reinfarction within 12 months 23 (2.2) 14 (1.5) 0.66 (0.34 to 1.28) 0.22 
    Unplanned revascularisation within 12 months 26 (2.5) 21 (2.2) 0.88 (0.49 to 1.56) 0.66 
    Stroke within 12 months 12 (1.2) 11 (1.2) 1.00 (0.44 to 2.26) 0.99 
        
Combined HHF and cardiac death within 30 days 83 (7.9) 78 (8.0) 1.01 (0.74 to 1.38) 0.93 
    Cardiac death within 30 days 15 (1.4) 17 (1.7) 1.22 (0.61 to 2.45) 0.57 
    HHF within 12 months 84 (8.0) 75 (7.7) 0.96 (0.71 to 1.32) 0.82 
        
MACCE within 30 days 42 (4.0) 35 (3.6) 0.90 (0.57 to 1.41) 0.65 
    All-cause mortality within 30 days 18 (1.7) 17 (1.7) 1.02 (0.53 to 1.98) 0.95 
    Reinfarction within 30 days 10 (1.0) 5 (0.5) 0.54 (0.18 to 1.58) 0.26 
    Unplanned revascularisation within 30 days 10 (1.0) 10 (1.0) 1.08 (0.45 to 2.60) 0.86 
    Stroke within 30 days 4 (0.4) 4 (0.4) 1.08 (0.27 to 4.32) 0.91 
        
ICD implantation within 12 months 5 (0.5) 7 (0.7) 1.51 (0.48 to 4.75) 0.48 
        
Repeat HHF, mean count (SD) 0.11 (0.40) 0.11 (0.40) 1.00 (0.73 to 1.36) 0.99 
Repeat HHF and Cardiac death, mean count (SD) 0.14 (0.47) 0.14 (0.48) 1.03 (0.76 to 1.40) 0.83 
 
For time-to-event outcomes, Kaplan-Meier estimates of the n (%) with the outcome at 30 days/12 months are 
presented. 
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval; HHF = hospitalization for heart 
failure; MACCE = composite of all-cause mortality, reinfarction, unplanned revascularisation, and stroke; ICD 
= implantable cardioverter-defibrillator; SD = standard deviation 
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Table S8. Subgroup Analyses for the CONDI-2 Trial (PP Analysis). 
 
 Control 
(n=1062) 
RIC 
(n=984) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Age (years), n (%)        
    <55 10 (3.7) 9 (3.7) 1.01 (0.41 to 2.50)  
    55-<65 24 (7.4) 22 (7.9) 1.06 (0.60 to 1.90)  
    65-<75 30 (11.0) 35 (12.3) 1.12 (0.69 to 1.83)  
    ≥75 40 (21.3) 34 (20.0) 0.92 (0.58 to 1.46) 0.95 
Medically treated diabetes, n (%)        
    No 85 (9.0) 81 (9.5) 1.06 (0.78 to 1.44)  
    Yes 19 (18.1) 19 (16.1) 0.86 (0.46 to 1.63) 0.56 
TIMI flow grade at admission, n (%)        
    TIMI 0-1 85 (12.2) 76 (12.0) 0.98 (0.72 to 1.34)  
    TIMI 2-3 19 (5.4) 24 (7.0) 1.32 (0.72 to 2.41) 0.40 
Infarct location, n (%)        
    Left anterior descending 74 (15.9) 73 (18.4) 1.18 (0.85 to 1.62)  
    Other 30 (5.1) 27 (4.7) 0.91 (0.54 to 1.53) 0.42 
First medical contact to balloon time (min), n (%)        
    <90 36 (7.7) 44 (10.4) 1.36 (0.88 to 2.12)  
    90-<120 34 (10.3) 27 (8.7) 0.83 (0.50 to 1.37)  
    120-≤720 34 (13.3) 29 (12.5) 0.94 (0.57 to 1.54) 0.30 
        
Exploratory analyses        
Gender, n (%)        
    Male 76 (9.2) 70 (9.4) 1.03 (0.74 to 1.42)  
    Female 28 (12.4) 30 (12.8) 1.03 (0.62 to 1.73) 0.99 
Smoking status, n (%)        
    Current smoker 35 (7.2) 43 (9.8) 1.37 (0.88 to 2.15)  
    Ex-smoker 33 (11.3) 22 (7.9) 0.69 (0.40 to 1.18)  
    Never smoked 32 (12.2) 33 (13.9) 1.15 (0.71 to 1.87) 0.14 
BMI (kg/m2), n (%)        
    <25 32 (10.3) 30 (10.5) 1.02 (0.62 to 1.68)  
    ≥25 69 (9.9) 68 (10.4) 1.05 (0.75 to 1.46) 0.94 
Symptom to balloon time (min), n (%)        
    <150 29 (6.7) 31 (8.1) 1.23 (0.74 to 2.03)  
    150-<240 33 (11.6) 27 (9.6) 0.82 (0.49 to 1.37)  
    240-≤720 33 (10.7) 37 (12.6) 1.18 (0.74 to 1.89) 0.48 
Hypertension, n (%)        
    No 54 (8.5) 54 (9.6) 1.15 (0.79 to 1.67)  
    Yes 50 (12.1) 46 (11.2) 0.92 (0.61 to 1.37) 0.43 
Beta-blockers, n (%)        
    No 82 (9.2) 89 (10.9) 1.20 (0.89 to 1.62)  
    Yes 20 (13.1) 11 (7.3) 0.53 (0.25 to 1.10) 0.04 
ACE-inhibitors, n (%)        
    No 83 (9.4) 84 (10.2) 1.08 (0.80 to 1.46)  
    Yes 19 (11.3) 16 (11.0) 0.96 (0.50 to 1.87) 0.76 
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 Control 
(n=1062) 
RIC 
(n=984) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Angiotensin II receptor blockers, n (%) 
    No 89 (9.5) 83 (9.9) 1.05 (0.78 to 1.41)  
    Yes 13 (11.3) 17 (12.3) 1.06 (0.52 to 2.19) 0.97 
Statins, n (%)        
    No 72 (8.8) 77 (10.2) 1.17 (0.85 to 1.61)  
    Yes 31 (13.2) 23 (10.6) 0.79 (0.46 to 1.35) 0.22 
Metformin, n (%)        
    No 87 (9.1) 83 (9.6) 1.06 (0.79 to 1.43)  
    Yes 10 (14.2) 9 (10.6) 0.71 (0.29 to 1.75) 0.41 
Sulphonylurea, n (%)        
    No 95 (9.4) 90 (9.6) 1.03 (0.77 to 1.37)  
    Yes 2 (11.8) 2 (13.3) 1.09 (0.15 to 7.72) 0.95 
Insulin, n (%)        
    No 99 (9.7) 90 (9.5) 0.99 (0.74 to 1.31)  
    Yes 5 (18.2) 10 (34.5) 2.09 (0.71 to 6.12) 0.18 
Ticagrelor, n (%)        
    No  103 (9.8) 100 (10.4) 1.06 (0.81 to 1.40)  
    Yes 1 (25.0) 0 (0.0) -   - 
 
This Table presents Kaplan-Meier estimates of the n (%) experiencing hospitalization for heart failure or 
cardiovascular death within 12 months.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval 
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Table S9. Baseline Characteristics of Patients and PPCI Procedure Details in the ERIC-PPCI Trial (ITT 
Analysis).  
          
 
Control RIC 
  (n=1297) (n=1268) 
Demographics 
    Age (years), mean (SD) 63.4 (12.3) 64.1 (12.1) 
              Missing, n 20 
 
22 
 Female, n (%) 282 (21.7) 289 (22.8) 
Missing, n 0 
 
0 
 Body mass index (BMI; kg/m2), mean (SD) 27.7 (5.0) 27.6 (5.0) 
Missing, n 73 
 
74 
 Current smokers, n (%) 444 (36.0) 444 (36.9) 
Missing, n 64 
 
65 
 
     Comorbidity, n (%) 
    Hypertension 519 (40.7) 548 (44.2) 
Missing, n 23 
 
27 
 Previous acute myocardial infarction (MI) 112 (8.7) 133 (10.6) 
Missing, n 14 
 
14 
 Hypercholesterolemia 368 (29.8) 379 (31.2) 
Missing, n 63 
 
54 
 Medically treated diabetes 141 (11.0) 146 (11.6) 
Missing, n 11 
 
11 
 Family history of ischaemic heart disease (IHD) 430 (36.8) 446 (40.2) 
Not known, n 129 
 
158 
 
     Medications at admission for PPCI, n (%) 
    Sulphonylurea 44 (3.4) 41 (3.3) 
Missing, n 16 
 
12 
 Metformin 113 (8.8) 115 (9.1) 
Missing, n 17 
 
10 
 Insulin 41 (3.2) 38 (3.0) 
Missing, n 18 
 
11 
 Clopidogrel 45 (3.5) 61 (4.9) 
Missing, n 18 
 
14 
 Ticagrelor 47 (3.7) 44 (3.5) 
Missing, n 17 
 
15 
 Prasugrel 3 (0.2) 3 (0.2) 
Missing, n 20 
 
14 
 Statins 352 (27.5) 355 (28.3) 
Missing, n 18 
 
15 
 Aspirin 234 (18.3) 260 (20.7) 
Missing, n 17 
 
14 
 Beta-blockers 197 (15.4) 200 (16.0) 
55 
 
Missing, n 21  17  
ACE inhibitors/Angiotensin receptor blockers 252 (19.7) 271 (21.7) 
               Missing, n           19 
 
          17 
 BP and Killip class at randomisation 
    Systolic blood pressure (mmHg), mean (SD) 132 (24) 133 (23) 
Missing, n 68 
 
74 
 Diastolic blood pressure (mmHg), mean (SD) 80 (16) 79 (15) 
Missing, n 70 
 
76 
 Killip class, n (%) 
    Class I 1269 (97.8) 1237 (97.6) 
Class II 21 (1.6) 19 (1.5) 
Class III 1 (0.1) 3 (0.2) 
Class IV (including cardiogenic shock) 6 (0.5) 9 (0.7) 
Missing, n 0 
 
0 
 
     RIC procedure 
    RIC procedure started, n (%) - 
 
1251 (98.7) 
Missing, n - 
 
0 
 Number of complete RIC cycles administered, n (%) 
    1 - 
 
33 (2.7) 
2 - 
 
28 (2.3) 
3 - 
 
80 (6.5) 
4 - 
 
1082 (88.5) 
Missing, n - 
 
28 
 
     PPCI procedure 
    PPCI completed, n (%) 1168 (90.1) 1142 (90.1) 
TIMI flow grade at admission, n (%) 
    TIMI 0 875 (76.6) 840 (74.9) 
TIMI 1 76 (6.6) 87 (7.8) 
TIMI 2 83 (7.3) 89 (7.9) 
TIMI 3 109 (9.5) 106 (9.4) 
Missing, n 25 
 
20 
 
Symptom to balloon time (min), median (IQR) 182 
(133 to 
279) 181 
(137 to 
281) 
Missing, n 154 
 
161 
 First medical contact to balloon time (min), median (IQR) 109 (90 to 132) 111 (92 to 137) 
Missing, n 172 
 
184 
 Infarct-related coronary artery, n (%) 
    Left anterior descending 493 (42.2) 477 (41.8) 
Circumflex 144 (12.3) 146 (12.8) 
Right coronary 529 (45.3) 515 (45.1) 
Other 2 (0.2) 3 (0.3) 
Missing, n 0 
 
1 
 Vessels with clinically significant disease, n (%) 
    0 1 (0.1) 2 (0.2) 
56 
 
1 660 (56.5) 623 (54.6) 
2 354 (30.3) 363 (31.8) 
3 153 (13.1) 154 (13.5) 
Missing, n 0 
 
0 
 Stenting of culprit lesion by PPCI, n (%) 1114 (95.4) 1096 (96.1) 
Missing, n 0 
 
1 
 Supplementary staged PCI, n (%) 102 (8.7) 97 (8.5) 
Supplementary staged CABG, n (%) 16 (1.4) 15 (1.3) 
TIMI flow grade after procedure, n (%) 
    TIMI 0 14 (1.2) 15 (1.3) 
TIMI 1 7 (0.6) 7 (0.6) 
TIMI 2 63 (5.5) 53 (4.7) 
TIMI 3 1054 (92.6) 1044 (93.3) 
Missing, n 30 
 
23 
 
     Medications given in relation to PPCI, n (%) 
    Opioids* 0   0   
Missing, n 1168 
 
1142 
 Heparin 1080 (92.5) 1071 (93.8) 
Missing, n 1 
 
0 
 Aspirin 1075 (92.2) 1056 (92.7) 
Missing, n 2 
 
3 
 Clopidogrel 380 (32.6) 348 (30.5) 
Missing, n 2 
 
1 
 Ticagrelor 791 (67.8) 793 (69.4) 
Missing, n 1 
 
0 
 Prasugrel 102 (8.7) 96 (8.4) 
Missing, n 2 
 
1 
 Nitrates 969 (83.0) 949 (83.1) 
Missing, n 1 
 
0 
 Glycoprotein IIb/IIIa inhibitor 307 (26.3) 274 (24.0) 
Missing, n 1 
 
0 
 Bivalirudin 63 (5.4) 63 (5.5) 
Missing, n 1 
 
0 
 Cangrelor* 0   0   
Missing, n 1168 
 
1142 
           
Abbreviations: RIC = remote ischemic conditioning; SD = standard deviation; IQR = interquartile range; BMI = 
body mass index; MI = myocardial infarction; IHD = ischemic heart disease; PPCI = primary percutaneous 
coronary intervention; BP = blood pressure; CABG = coronary artery bypass graft surgery  
*Opioids and cangrelor data collected only in CONDI-2. 
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Table S10. Primary and Secondary Outcomes in the ERIC-PPCI Trial (ITT Analysis). 
 
 Control 
(n=1297) 
RIC 
(n=1268) 
Treatment effect, p-value 
 RIC vs Control 
 (95% CI) 
Primary outcome, n (%)        
Combined HHF and cardiac death within 12 months 91 (7.0) 109 (8.6) 1.23 (0.93 to 1.63) 0.14 
    Cardiac death within 12 months 38 (2.9) 36 (2.8) 0.97 (0.62 to 1.54) 0.91 
    HHF within 12 months 64 (5.0) 78 (6.2) 1.25 (0.90 to 1.74) 0.18 
        
Secondary outcomes, n (%)        
MACCE within 12 months 88 (6.8) 101 (8.0) 1.18 (0.89 to 1.57) 0.25 
    All-cause mortality within 12 months 52 (4.0) 60 (4.8) 1.19 (0.82 to 1.72) 0.37 
    Reinfarction within 12 months 16 (1.3) 16 (1.3) 1.03 (0.51 to 2.06) 0.94 
    Unplanned revascularisation within 12 months 32 (2.5) 35 (2.9) 1.13 (0.70 to 1.82) 0.62 
    Stroke within 12 months 6 (0.5) 9 (0.7) 1.55 (0.55 to 4.34) 0.41 
        
Combined HHF and cardiac death within 30 days 82 (6.3) 101 (8.0) 1.27 (0.95 to 1.70) 0.11 
    Cardiac death within 30 days 27 (2.1) 33 (2.6) 1.25 (0.75 to 2.09) 0.38 
    HHF within 12 months 59 (4.6) 72 (5.7) 1.25 (0.89 to 1.77) 0.20 
        
MACCE within 30 days 48 (3.7) 61 (4.8) 1.31 (0.90 to 1.91) 0.16 
    All-cause mortality within 30 days 29 (2.2) 37 (2.9) 1.31 (0.81 to 2.13) 0.28 
    Reinfarction within 30 days 10 (0.8) 12 (1.0) 1.23 (0.53 to 2.85) 0.63 
    Unplanned revascularisation within 30 days 18 (1.4) 17 (1.4) 0.97 (0.50 to 1.88) 0.93 
    Stroke within 30 days 3 (0.2) 5 (0.4) 1.71 (0.41 to 7.18) 0.46 
        
ICD implantation within 12 months 22 (1.8) 29 (2.4) 1.36 (0.78 to 2.35) 0.27 
        
Repeat HHF, mean count (SD) 0.06 (0.32) 0.07 (0.28) 1.10 (0.78 to 1.55) 0.59 
Repeat HHF and cardiac death, mean count (SD) 0.09 (0.38) 0.10 (0.33) 1.06 (0.79 to 1.42) 0.70 
 
For time-to-event outcomes, Kaplan-Meier estimates of the n (%) with the outcome at 30 days/12 months are 
presented.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval; HHF = hospitalization for heart 
failure; MACCE = composite of all-cause mortality, reinfarction, unplanned revascularisation, and stroke; ICD 
= implantable cardioverter-defibrillator; SD = standard deviation 
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Table S11. Subgroup Analyses for the ERIC-PPCI Trial (ITT analysis). 
 
 Control 
(n=1297) 
RIC 
(n=1268) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Age (years), n (%)        
    <55 8 (2.3) 10 (3.3) 1.47 (0.58 to 3.71)  
    55-<65 14 (3.7) 18 (5.4) 1.45 (0.72 to 2.92)  
    65-<75 20 (6.6) 25 (6.9) 1.06 (0.59 to 1.90)  
    ≥75 30 (12.2) 37 (14.9) 1.23 (0.76 to 1.99) 0.89 
Medically treated diabetes, n (%)        
    No 76 (6.6) 87 (7.9) 1.19 (0.87 to 1.61)  
    Yes 13 (9.3) 19 (13.1) 1.43 (0.71 to 2.90) 0.63 
TIMI flow grade at admission, n (%)        
    TIMI 0-1 67 (6.8) 89 (9.3) 1.37 (1.00 to 1.88)  
    TIMI 2-3 16 (6.1) 15 (5.7) 0.95 (0.47 to 1.92) 0.35 
Infarct location, n (%)        
    Left anterior descending 54 (10.4) 68 (13.5) 1.31 (0.92 to 1.88)  
    Other 33 (4.7) 38 (5.4) 1.17 (0.74 to 1.87) 0.71 
First medical contact to balloon time (min), n (%)        
    <90 7 (2.7) 9 (3.6) 1.34 (0.50 to 3.61)  
    90-<120 28 (6.2) 31 (8.0) 1.31 (0.78 to 2.18)  
    120-≤720 37 (9.2) 45 (10.2) 1.12 (0.72 to 1.73) 0.88 
        
Exploratory analyses        
Gender, n (%)        
    Male 63 (6.2) 78 (8.0) 1.29 (0.93 to 1.80)  
    Female 28 (9.9) 31 (10.8) 1.08 (0.65 to 1.81) 0.57 
Smoking status, n (%)        
    Current smoker 18 (4.1) 26 (5.9) 1.45 (0.80 to 2.65)  
    Ex-smoker 32 (8.0) 29 (7.6) 0.95 (0.57 to 1.57)  
    Never smoked 34 (8.8) 41 (10.9) 1.26 (0.80 to 1.99) 0.53 
BMI (kg/m2), n (%)        
    <25 24 (6.1) 30 (8.0) 1.32 (0.77 to 2.26)  
    ≥25 56 (6.8) 65 (8.0) 1.18 (0.83 to 1.69) 0.74 
Symptom to balloon time (min), n (%)        
    <150 15 (3.6) 27 (7.5) 2.10 (1.12 to 3.94)  
    150-<240 26 (7.2) 32 (8.1) 1.13 (0.67 to 1.89)  
    240-≤720 31 (9.0) 26 (7.9) 0.87 (0.52 to 1.46) 0.10 
Hypertension, n (%)        
    No 47 (6.2) 42 (6.1) 0.97 (0.64 to 1.47)  
    Yes 40 (7.7) 61 (11.2) 1.47 (0.99 to 2.19) 0.16 
Beta-blockers, n (%)        
    No 67 (6.2) 78 (7.4) 1.20 (0.87 to 1.66)  
    Yes 18 (9.1) 26 (13.0) 1.46 (0.80 to 2.66) 0.58 
ACE-inhibitors, n (%)        
    No 65 (6.3) 76 (7.8) 1.23 (0.88 to 1.72)  
    Yes 20 (8.0) 28 (10.4) 1.32 (0.74 to 2.34) 0.84 
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 Control 
(n=1297) 
RIC 
(n=1268) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Angiotensin II receptor blockers, n (%) 
    No 75 (6.5) 92 (8.2) 1.27 (0.94 to 1.73)  
    Yes 11 (9.7) 12 (10.0) 1.04 (0.46 to 2.36) 0.65 
Statins, n (%)        
    No 62 (6.7) 73 (8.1) 1.22 (0.87 to 1.71)  
    Yes 25 (7.1) 31 (8.8) 1.24 (0.73 to 2.11) 0.95 
Metformin, n (%)        
    No 81 (7.0) 93 (8.2) 1.18 (0.88 to 1.59)  
    Yes 6 (5.3) 12 (10.5) 2.01 (0.76 to 5.36) 0.31 
Sulphonylurea, n (%)        
    No 84 (6.8) 100 (8.3) 1.22 (0.91 to 1.63)  
    Yes 3 (6.8) 5 (12.4) 1.79 (0.43 to 7.50) 0.61 
Insulin, n (%)        
    No 80 (6.5) 97 (8.0) 1.24 (0.92 to 1.67)  
    Yes 7 (17.2) 8 (21.1) 1.24 (0.45 to 3.41) 0.99 
Ticagrelor, n (%)        
    No 34 (8.8) 35 (10.0) 1.13 (0.71 to 1.81)  
    Yes 45 (5.6) 57 (7.2) 1.07 (0.87 to 1.89) 0.70 
 
This Tables presents Kaplan-Meier estimates of the n (%) experiencing hospitalization for heart failure or 
cardiovascular death within 12 months. 
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval 
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Table S12. Baseline Characteristics of Patients and PPCI Procedure Details in the ERIC-PPCI Trial (PP 
Analysis).  
          
 
Control RIC 
  (n=1143) (n=1024) 
Demographics 
    Age (years), mean (SD) 63.3 (12.1) 64.4 (11.8) 
Missing, n 12 
 
11 
 Female, n (%) 239 (20.9) 221 (21.6) 
Missing, n 0 
 
0 
 Body mass index (BMI; kg/m2), mean (SD) 27.7 (5.0) 27.6 (4.9) 
Missing, n 63 
 
48 
 Current smokers, n (%) 408 (37.4) 356 (36.5) 
Missing, n 52 
 
49 
 
     Comorbidity, n (%) 
    Hypertension 448 (39.9) 442 (44.1) 
Missing, n 20 
 
21 
 Previous acute myocardial infarction (MI) 87 (7.7) 100 (9.9) 
Missing, n 11 
 
11 
 Hypercholesterolemia 325 (29.8) 303 (30.8) 
Missing, n 53 
 
41 
 Medically treated diabetes 120 (10.6) 126 (12.4) 
Missing, n 9 
 
8 
 Family history of ischaemic heart disease (IHD) 386 (37.3) 368 (40.8) 
Not known, n 109 
 
121 
 
     Medications at admission for PPCI, n (%) 
    Sulphonylurea 37 (3.3) 37 (3.6) 
Missing, n 11 
 
8 
 Metformin 98 (8.7) 98 (9.6) 
Missing, n 12 
 
6 
 Insulin 35 (3.1) 35 (3.4) 
Missing, n 13 
 
7 
 Clopidogrel 41 (3.6) 50 (4.9) 
Missing, n 14 
 
9 
 Ticagrelor 46 (4.1) 39 (3.8) 
Missing, n 12 
 
9 
 Prasugrel 3 (0.3) 2 (0.2) 
Missing, n 15 
 
9 
 Statins 308 (27.3) 284 (28.0) 
Missing, n 14 
 
8 
 Aspirin 199 (17.6) 217 (21.4) 
Missing, n 12 
 
9 
 Beta-blockers 168 (14.9) 165 (16.3) 
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Missing, n 17  12  
ACE inhibitors/Angiotensin receptor blockers 213 (18.9) 206 (20.4) 
Missing, n 15  12  
Beta-blockers 168 (14.9) 165 (16.3) 
BP and Killip class at randomisation 
    Systolic blood pressure (mmHg), mean (SD) 132 (24) 133 (23) 
Missing, n 48 
 
42 
 Diastolic blood pressure (mmHg), mean (SD) 79 (16) 79 (15) 
Missing, n 50 
 
43 
 Killip class, n (%) 
    Class I 1119 (97.9) 996 (97.3) 
Class II 18 (1.6) 17 (1.7) 
Class III 0 (0.0) 3 (0.3) 
Class IV (including cardiogenic shock) 6 (0.5) 8 (0.8) 
Missing, n 0 
 
0 
 
     RIC procedure 
    RIC procedure started, n (%) - 
 
1024 (100.0) 
Missing, n - 
 
0 
 Number of complete RIC cycles administered, n (%) 
    1 - 
 
4 (0.4) 
2 - 
 
4 (0.4) 
3 - 
 
42 (4.2) 
4 - 
 
961 (95.1) 
Missing, n - 
 
13 
 
     PPCI procedure 
    PPCI completed, n (%) 1143 (100.0) 1024 (100.0) 
TIMI flow grade at admission, n (%) 
    TIMI 0 858 (76.7) 746 (74.3) 
TIMI 1 74 (6.6) 78 (7.8) 
TIMI 2 82 (7.3) 80 (8.0) 
TIMI 3 105 (9.4) 100 (10.0) 
Missing, n 24 
 
20 
 
Symptom to balloon time (min), median (IQR) 182 
(133 to 
279) 181 
(137 to 
284) 
Missing, n 24 
 
33 
 First medical contact to balloon time (min), median (IQR) 109 (90 to 132) 112 (92 to 137) 
Missing, n 41 
 
54 
 Infarct-related coronary artery, n (%) 
    Left anterior descending 480 (42.0) 438 (42.8) 
Circumflex 140 (12.2) 127 (12.4) 
Right coronary 522 (45.7) 456 (44.6) 
Other 1 (0.1) 2 (0.2) 
Missing, n 0 
 
1 
 Vessels with clinically significant disease, n (%) 
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0 1 (0.1) 2 (0.2) 
1 644 (56.3) 559 (54.6) 
2 346 (30.3) 324 (31.6) 
3 152 (13.3) 139 (13.6) 
Missing, n 0 
 
0 
 Stenting of culprit lesion by PPCI, n (%) 1090 (95.4) 981 (95.9) 
Missing, n 0 
 
1 
 Supplementary staged PCI, n (%) 102 (8.9) 83 (8.1) 
Supplementary staged CABG, n (%) 16 (1.4) 12 (1.2) 
TIMI flow grade after procedure, n (%) 
    TIMI 0 14 (1.3) 15 (1.5) 
TIMI 1 7 (0.6) 7 (0.7) 
TIMI 2 62 (5.6) 47 (4.7) 
TIMI 3 1031 (92.5) 932 (93.1) 
Missing, n 29 
 
23 
 
     Medications administered in relation to PPCI, n (%) 
    Opioids* 0   0   
Missing, n 1143 
 
1024 
 Heparin 1055 (92.4) 958 (93.6) 
Missing, n 1 
 
0 
 Aspirin 1055 (92.5) 945 (92.6) 
Missing, n 2 
 
3 
 Clopidogrel 370 (32.4) 309 (30.2) 
Missing, n 2 
 
1 
 Ticagrelor 782 (68.5) 719 (70.2) 
Missing, n 1 
 
0 
 Prasugrel 97 (8.5) 81 (7.9) 
Missing, n 2 
 
1 
 Nitrates 950 (83.2) 851 (83.1) 
Missing, n 1 
 
0 
 Glycoprotein IIb/IIIa inhibitor 302 (26.4) 242 (23.6) 
Missing, n 1 
 
0 
 Bivalirudin 63 (5.5) 60 (5.9) 
Missing, n 1 
 
0 
 Cangrelor* 0   0   
Missing, n 1143 
 
1024 
           
Abbreviations: RIC = remote ischemic conditioning; SD = standard deviation; IQR = interquartile range; BMI = 
body mass index; MI = myocardial infarction; IHD = ischemic heart disease; PPCI = primary percutaneous 
coronary intervention; BP = blood pressure; CABG = coronary artery bypass graft surgery  
*Opioids and cangrelor data collected only in CONDI-2. 
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Table S13. Primary and Secondary Outcomes in the ERIC-PPCI Trial (PP Analysis). 
 
 Control 
(n=1143) 
RIC 
(n=1024) 
Treatment effect, p-value 
 RIC vs Control 
 (95% CI) 
Primary outcome, n (%)        
Combined HHF and cardiac death within 12 months 178 (8.1) 179 (9.0) 1.11 (0.90 to 1.36) 0.35 
    Cardiac death within 12 months 50 (2.3) 51 (2.6) 1.12 (0.76 to 1.66) 0.56 
    HHF within 12 months 154 (7.0) 147 (7.4) 1.05 (0.83 to 1.31) 0.70 
        
Secondary outcomes, n (%)        
MACCE within 12 months 159 (7.3) 160 (8.0) 1.11 (0.89 to 1.38) 0.35 
    All-cause mortality within 12 months 73 (3.3) 85 (4.3) 1.29 (0.94 to 1.76) 0.12 
    Reinfarction within 12 months 37 (1.7) 27 (1.4) 0.80 (0.49 to 1.32) 0.38 
    Unplanned revascularisation within 12 months 54 (2.5) 51 (2.6) 1.05 (0.71 to 1.53) 0.81 
    Stroke within 12 months 17 (0.8) 20 (1.0) 1.30 (0.68 to 2.47) 0.43 
        
Combined HHF and cardiac death within 30 days 153 (7.0) 151 (7.5) 1.08 (0.87 to 1.36) 0.48 
    Cardiac death within 30 days 33 (1.5) 38 (1.9) 1.27 (0.80 to 2.02) 0.32 
    HHF within 12 months 140 (6.4) 130 (6.5) 1.02 (0.80 to 1.29) 0.89 
        
MACCE within 30 days 78 (3.6) 79 (4.0) 1.12 (0.82 to 1.53) 0.49 
    All-cause mortality within 30 days 37 (1.7) 40 (2.0) 1.19 (0.76 to 1.86) 0.44 
    Reinfarction within 30 days 19 (0.9) 14 (0.7) 0.81 (0.41 to 1.62) 0.55 
    Unplanned revascularisation within 30 days 26 (1.2) 24 (1.2) 1.02 (0.59 to 1.78) 0.94 
    Stroke within 30 days 7 (0.3) 9 (0.5) 1.42 (0.53 to 3.80) 0.49 
        
ICD implantation within 12 months 24 (1.1) 28 (1.4) 1.28 (0.75 to 2.21) 0.37 
        
Repeat HHF, mean count (SD) 0.09 (0.37) 0.09 (0.35) 1.00 (0.79 to 1.27) 0.99 
Repeat HHF and cardiac death, mean count (SD) 0.11 (0.43) 0.11 (0.41) 1.03 (0.82 to 1.29) 0.83 
 
For time-to-event outcomes, Kaplan-Meier estimates of the n (%) with the outcome at 30 days/12 months are 
presented. 
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval; HHF = hospitalization for heart 
failure; MACCE = composite of all-cause mortality, reinfarction, unplanned revascularisation, and stroke; ICD 
= implantable cardioverter-defibrillator; SD = standard deviation 
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Table S14. Subgroup Analyses for the ERIC-PPCI Trial (PP Analysis). 
 
 Control 
(n=1143) 
RIC 
(n=1024) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Age (years), n (%)        
    <55 18 (3.1) 14 (2.9) 0.93 (0.46 to 1.87)  
    55-<65 37 (5.6) 34 (6.1) 1.09 (0.69 to 1.74)  
    65-<75 48 (8.8) 55 (9.5) 1.09 (0.74 to 1.60)  
    ≥75 64 (16.0) 66 (17.4) 1.09 (0.77 to 1.54) 0.98 
Medically treated diabetes, n (%)        
    No 148 (7.5) 143 (8.2) 1.09 (0.86 to 1.37)  
    Yes 29 (12.9) 35 (14.4) 1.09 (0.67 to 1.79) 0.98 
TIMI flow grade at admission, n (%)        
    TIMI 0-1 142 (8.7) 142 (9.8) 1.12 (0.89 to 1.41)  
    TIMI 2-3 31 (5.8) 35 (6.7) 1.18 (0.73 to 1.91) 0.85 
Infarct location, n (%)        
    Left anterior descending 120 (12.7) 127 (15.2) 1.22 (0.95 to 1.57)  
    Other 58 (4.6) 52 (4.5) 0.95 (0.65 to 1.38) 0.28 
First medical contact to balloon time (min), n (%)        
    <90 43 (6.0) 50 (7.8) 1.31 (0.87 to 1.97)  
    90-<120 61 (7.8) 54 (8.2) 1.02 (0.70 to 1.47)  
    120-≤720 70 (10.8) 69 (10.9) 1.03 (0.74 to 1.43) 0.59 
        
Exploratory analyses        
Gender, n (%)        
    Male 129 (7.5) 128 (8.3) 1.12 (0.87 to 1.42)  
    Female 49 (10.5) 51 (11.2) 1.05 (0.71 to 1.56) 0.81 
Smoking status, n (%)        
    Current smoker 50 (5.6) 61 (7.7) 1.38 (0.95 to 2.00)  
    Ex-smoker 57 (8.8) 44 (7.5) 0.83 (0.56 to 1.23)  
    Never smoked 62 (10.5) 65 (12.0) 1.15 (0.81 to 1.63) 0.18 
BMI (kg/m2), n (%)        
    <25 51 (7.8) 54 (9.2) 1.18 (0.81 to 1.73)  
    ≥25 116 (8.1) 117 (8.8) 1.08 (0.84 to 1.40) 0.71 
Symptom to balloon time (min), n (%)        
    <150 43 (5.1) 54 (7.7) 1.50 (1.01 to 2.24)  
    150-<240 58 (9.1) 52 (8.2) 0.91 (0.62 to 1.32)  
    240-≤720 64 (9.9) 62 (10.4) 1.05 (0.74 to 1.48) 0.18 
Hypertension, n (%)        
    No 93 (7.1) 88 (7.8) 1.11 (0.83 to 1.48)  
    Yes 82 (9.5) 88 (10.3) 1.08 (0.80 to 1.46) 0.92 
Beta-blockers, n (%)        
    No 139 (7.5) 146 (8.8) 1.17 (0.93 to 1.48)  
    Yes 32 (10.0) 30 (9.4) 0.93 (0.56 to 1.53) 0.41 
ACE-inhibitors, n (%)        
    No 139 (7.7) 143 (8.8) 1.13 (0.89 to 1.43)  
    Yes 32 (8.4) 33 (9.4) 1.13 (0.69 to 1.84) 1.00 
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 Control 
(n=1143) 
RIC 
(n=1024) 
Treatment effect, Interaction 
p-value  RIC vs. Control 
 (95% CI) 
Angiotensin II receptor blockers, n (%) 
    No 149 (7.6) 150 (8.6) 1.14 (0.91 to 1.43)  
    Yes 23 (10.8) 26 (10.9) 0.97 (0.56 to 1.71) 0.61 
Statins, n (%)        
    No 123 (7.5) 131 (8.8) 1.18 (0.92 to 1.51)  
    Yes 51 (9.4) 46 (9.2) 0.97 (0.65 to 1.45) 0.43 
Metformin, n (%)        
    No 152 (7.6) 151 (8.5) 1.11 (0.89 to 1.39)  
    Yes 16 (9.5) 18 (9.8) 1.00 (0.51 to 1.96) 0.77 
Sulphonylurea, n (%)        
    No 164 (7.8) 163 (8.5) 1.09 (0.88 to 1.36)  
    Yes 4 (7.4) 6 (11.8) 1.55 (0.44 to 5.49) 0.60 
Insulin, n (%)        
    No 166 (7.8) 159 (8.3) 1.05 (0.85 to 1.31)  
    Yes 9 (14.5) 18 (28.2) 2.08 (0.93 to 4.62) 0.11 
Ticagrelor, n (%)        
    No 70 (6.5) 77 (7.9) 1.23 (0.89 to 1.70)  
    Yes 1 (2.2) 1 (2.6) 1.18 (0.07 to 18.87) 0.98 
 
This Tables presents Kaplan-Meier estimates of the n (%) experiencing hospitalization for heart failure or 
cardiovascular death within 12 months.  
Abbreviations: RIC = remote ischemic conditioning; CI = confidence interval 
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Table S15. MI size quantified by AUC for troponin T over 48 hours for CONDI-2/ERIC-PPCI trial 
 Control RIC Treatment effect, p-value 
 RIC vs Control 
 (95% CI) 
Biomarker Substudy     
AUC for troponin T (ng*hr/ml)        
     Median (IQR) 91.9 (37.6 to 185.6) 110.3 (48.0 to 218.5)    
     N with complete data 363 345    
     N with multiple imputation 1,330 1,332 1.05 (0.92 to 1.18) 0.48 
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Introduction 
Title Effect of Remote Ischaemic Conditioning on clinical  
outcomes in ST-elevation myocardial infarction patients  
undergoing primary Percutaneous Coronary Intervention:  
A multicentre randomised controlled clinical study 
Acronym Condi 2 
Sponsor Aarhus University Hospital 
Regional Scientific 
Ethical Committee of 
Central Denmark 
No. 1-10-72-167-13 
 
Condi 2 is a randomised controlled trial to determine whether remote ischaemic conditioning (RIC) 
improves clinical outcomes after in patients with ST-segment elevation myocardial infarction 
undergoing Primary Percutaneous Coronary Intervention (PPCI).  Prof Hans Erik Bøtker (Aarhus 
University Hospital, Dk) is the Chief Investigator and the trial is managed by the Clinical Trials Unit at 
Aarhus University Hospital (AUH).  
The intervention is non-pharmacological. Patients are randomised to one of two groups: 
Conventional treatment (control) or Remote Ischaemic Conditioning (RIC). The RIC treatment is 
applied during ambulance transportation to the hospital. Automated CellAegis autoRIC™ cuff devices 
will be used to deliver the RIC protocols. The active RIC treatment consists of four 5-minute 
inflations of the autoRIC™ cuff on the upper arm to 200mmHg, separated by 5-minute periods when 
the cuff will be deflated. For patients presenting with a systolic blood pressure (SBP) ≥175mmHg, a 
manual blood pressure cuff will be used and inflated to 25 mmHg above systolic blood pressure.  
The reporting of final results from the Condi 2 trial will be conducted in collaboration with Prof 
Derek Hausenloy (University College London, UK), who is Chief Investigator of the ERIC-PPCI trial , in 
order to maximise power to assess the impact of RIPC on clinical endpoints. In total 4300 STEMI 
patients will be recruited: 2300 STEMI patients will be randomised to CONDI 2 (Figure 1) and 2000 
STEMI patients will be randomised to ERIC-PPCI (Figure 2)  
Primary endpoint 
The primary endpoint is occurrence of cardiac death and hospitalisation for heart failure (HHF) in 
STEMI patients 12 months after PPCI.  
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Major secondary endpoints 
1. Cardiac death and HHF at 30 days post PPCI.  
2. All-cause death at 30 days and 12 months. 
3. Repeat coronary revascularisation at 30 days and 12 months. 
4. Reinfarction at 30 days and 12 months. 
5. Stroke at 30 days and 12 months. 
6. Left ventricular function on day three and three-six months post pPCI (Echocardiography) 
7. Myocardial infarct size at day 3 (72 hour area under curve serum creatinine kinase)  
8. Quality of life at 6-8 weeks and 12 months (EuroQol EQ-5D-5L) 
 
Sub-studies 
1. Persisting ST-segment elevation on ECG 90 min. after primary PCI  
2. Myocardial infarct size at day three (72 hour area under curve serum creatinine kinase). 
Furthermore, TnT in a subset of patients (Aarhus, Aalborg, Belgrade) 
3. Left ventricular function on day three and three months post pPCI (Echocardiography) 
 
Clinical outcome data will be collected at the telephone or outpatient follow-up at 6-12 weeks and 
one year post-PPCI. The source data for the events are print-outs from the electronic medical record 
of each patient. Furthermore, documents from “The West-Danish heart database” or “The East-
Danish Heart database”. Data documentation in Spain and Serbia are prints of the electronic or 
paper medical record of each patient. 
Outline of scope of charter  
The purpose of this document is to describe the roles and responsibilities of the independent DSMC 
for the Condi 2 trial, including the timing of meetings, methods of providing information to and from 
the DSMC, frequency and format of meetings, statistical issues and relationships with other 
committees. 
The following documents were reviewed in preparation of this charter: 
 CONDI-2 trial protocol Version 10.4 29th Oct 2015 
 ERIC-PPCI trial protocol version 2, issued 24th Feb 2015 
 Case report form (CRF) version 1, issued 22nd April 2014 
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 London School of Hygiene and Tropical Medicine (LSHTM) Template charter for DMCs, 
issued 7th July 2015 
 DAMOCLES study group proposed charter for data monitoring committees data monitoring 
committees1 
Roles and responsibilities 
The DSMC role is to examine the data accumulated during progress of the Condi 2 trial and ensure 
that the benefit/risk ratio remains acceptable for participating patients. It is the only committee 
which will have access to data broken down by treatment during the trial and on this basis, the 
primary responsibility of the DSMC is to review interim analyses of outcome data and to recommend 
to the Trial Steering Committee (TSC) whether the trial needs to be changed or terminated based on 
these analyses. 
More specifically, the duties of the DSMC will include: 
 monitoring evidence for treatment differences in the primary and secondary endpoints  
 monitoring evidence for treatment harm (e.g. SAEs, deaths) 
 assessing the impact and relevance of external evidence, particularly any DSMC 
recommendations from the ongoing ERIC-PPCI trial 
 deciding whether to recommend that the trial continues to recruit participants or whether 
recruitment should be terminated either for everyone or for some treatment groups and/or 
some participant subgroups  
 assessing data quality, including completeness  
 reviewing recruitment figures and monitor losses to follow-up 
 monitoring compliance with the protocol by participants and investigators 
 monitoring continuing appropriateness of patient information 
 monitoring compliance with previous DSMC recommendations 
 considering the ethical implications of any recommendations made by the DSMC 
                                                 
1 DAMOCLES Study Group (2005) A proposed charter for clinical trial data monitoring 
committees: helping them to do their job well. Lancet. 365: 711-22. 
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DSMC input early in the trial 
All potential DSMC members should have sight of the trial protocol before finalising their agreement 
to join the committee. Before recruitment begins the trial will have undergone review by the 
sponsor, scrutiny by other trial committees and a research ethics committee. Therefore, if a 
potential DSMC member has major reservations about the trial (e.g. the protocol or the logistics) 
they should report these to the Dept. Cardiology, Clinical Trials Unit, AUH and may decide not to 
accept the invitation to join. DSMC members should be independent and constructively critical of 
the ongoing trial, but also supportive of aims and methods of the trial. 
Initial DSMC meeting 
The first DSMC meeting will be held primo 2016 and hereafter then at least annually depending on 
the rate of accrual of data.  
A DSMC statistical analysis plan, including a list of tables, will be provided prior to the initial meeting 
to familiarise the DSMC members with the intended content of the DSMC reports. The DSMC will 
review the statistical analysis plan at the first meeting and confirm the content of the report to be 
provided at subsequent meetings. Alterations to the report can be made at subsequent meetings to 
reflect the requirements of the DSMC.  
DSMC composition 
All members of the DSMC have previous expertise in trials.  
The members of the DSMC for this trial are:  
Chair:  Henning Kelbæk, Independent interventional cardiologist 
Hector Bueno, Independent interventional cardiologist  
Morten Madsen, Independent Senior medical statistician  
Jakob Hjort, Independent data manager 
All DSMC members will maintain confidentiality, review available reports prior to meetings and 
contribute actively to developing the DSMC recommendations 
The DSMC Chair will communicate the written recommendations of the DSMC to the Chair of the 
TSC, determine whether additional meetings are required, and maintain documentation of 
communication between the DSMC and the TSC. 
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The independent statistician supplying the DSMC, Morten Madsen, will produce the confidential 
interim reports for the DSMC and distribute these at least one week prior to each meeting. He will 
also participate in DSMC meetings, guiding the DSMC through the report, and contributing to DSMC 
discussions. The statistician will also prepare and distribute meeting minutes to DSMC members as 
password protected files within one week after each meeting. 
The Chief Investigator, Prof Hans Erik Bøtker, and/or relevant members of the Condi 2 Clinical Trials 
Unit will be invited to join the open session of the DSMC meeting to provide an update on trial 
progress. The Condi 2 Clinical Trials Unit will provide a report on trial progress for discussion during 
the open session, for example recruitment, trial conduct etc.  
See Table 1 for full contact details of the DSMC and Independent Statistician. 
DSMC membership and their obligations 
Members of a DSMC are required to: 
(1) Confirm their agreement to take on the responsibilities of membership as outlined in this 
Charter  
(2) Agree to maintain the confidentiality of the data provided and the deliberations of the 
Committee 
(3) Have no conflict of interest which will prejudice their role as a DSMC member 
By agreeing to adopt this Charter, all members confirm the above. 
Relationships 
Figure 3 details the organisation of the Condi 2 trial and the reporting structure for the DSMC. The 
DSMC does not make decisions about the trial, but rather makes recommendations to the TSC. 
As data from Condi 2 will be combined with data from ERIC-PPCI for the reporting of final results, it 
is intended that the TSC for both trials will be copied into the recommendations of each trial’s DSMC 
to the TSC. If a decision is reached to stop or modify either trial, this will be immediately 
communicated to the relevant committees of both trials. 
Payments to DSMC members 
Members will be reimbursed for standard class travel for DSMC duties.  
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The need for DSMC members to disclose information about any competing 
interests 
All competing interests should be disclosed prior to agreeing this Charter.  These are not restricted 
to financial matters – involvement in other trials or intellectual investment could be relevant.  
Although members may well be able to act objectively despite such connections, complete 
disclosure helps to enhance credibility (see Annex 1). 
DSMC members should not use interim results to inform trading in pharmaceutical shares, and 
careful consideration should be given to trading in stock of companies with competing products. 
DSMC organisation 
DSMC meetings will be conducted to review interim data. It is intended that the DSMC will meet to 
review interim results after 3-6 months of recruitment and then at least annually depending on the 
rate of accrual of data. 
The DSMC will decide on the type of meeting required (face-to-face or teleconference). The Condi 2 
Clinical Trials Unit will make arrangements accordingly. 
The format of the meetings will be as follows: 
1. Open session: Introduction and any “open” parts of the report 
2. Closed session: DSMC discussion of “closed” parts of the report  
Attendance at open and closed sessions 
In the open session all those attending the closed session are joined by the Chief Investigator and/or 
relevant members of the Condi 2 Clinical Trials Unit. External experts may also be invited to the 
DSMC meetings at the request of the DSMC members. No unblinded data will be discussed during 
this session.  
In the closed session only members of the DSMC and others whom they specifically invite (e.g. 
Independent Statistician) will be present. The unblinded interim results will be discussed and the 
DSMC will decide on their recommendation to the Trial Steering Committee (TSC). 
DSMC closed session discussions will remain confidential and will not be communicated to the Condi 
2 Clinical Trials Unit. 
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Trial documentation and procedures to ensure confidentiality and 
proper communication 
Data for preparation of the interim report will be accessed by Morten Madsen from the trial 
database using a unique username and password. In addition to this report, the DSMC will be 
provided with an update on trial progress from the Condi 2 Clinical Trials Unit. These documents will 
be circulated at least 1 week in advance of the DSMC meeting.  
The interim reports on the ERIC-PPCI trial will be copied to the Condi 2 DSMC members for 
consideration alongside the unblinded Condi 2 report. Similarly the interim reports from the Condi 2 
trial will be copied to the ERIC-PPCI DSMC members for consideration alongside the ERIC-PPCI 
report. 
Intended content of material to be available 
Open sessions: Accumulating information relating to recruitment and data quality (e.g. data 
return rates) will be presented.   
Closed sessions: In addition to all the material available in the open session, the closed session 
material will include safety and efficacy data by treatment group. The unblinded ERIC-PPCI 
interim reports from previous meetings of the ERIC-PPCI DSMC will also be available at this 
session. 
 
The unblinded interim reports will contain details of: 
1. Patient recruitment 
2. Demographic and baseline characteristics 
3. Details of the RIC intervention 
4. Treatment times for PPCI (onset to balloon, door to balloon, 1st ECG to balloon times) 
5. IV medications given during PPCI 
6. Mortality and other safety endpoints 
7. Primary efficacy endpoint - cardiac death and HHF 
8. Unexpected Adverse and Serious Adverse Events 
9. Other endpoints identified by the DSMC  
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The DSMC members should store the papers safely after each meeting so they may check the next 
report against them.  After the trial is reported, the DSMC members may destroy all interim reports.  
 
DSMC recommendations and decision making 
Possible recommendations could include:- 
 No action needed, trial continues as planned  
 Early stopping due, for example, to clear benefit or harm of a treatment, futility, or external 
evidence  
 Stopping recruitment within a subgroup 
 Extending recruitment (based on actual control arm response rates being different to 
predicted rather than on emerging differences) or extending follow-up 
 Sanctioning and/or proposing protocol changes 
Interim analyses and stopping rules 
It is not expected that the trial will be stopped for reasons of efficacy or futility based on observed 
treatment differences. A robust demonstration of efficacy is required to dispel scepticism that this 
simple intervention may be effective. Similarly, if there is no effect of the intervention then stopping 
for futility will reduce the ability to demonstrate this. Therefore the primary reason to recommend 
stopping the trial will be for safety reasons. 
For the primary outcome, the DSMC will consider stopping if there is evidence of a difference in rate 
between the RIC and control group achieving p < 0.001. 
For the main safety endpoints (e.g. mortality) the DSMC will consider stopping if there is evidence of 
greater event rate in the RIC group achieving p < 0.01. 
How decisions or recommendations will be reached within the DSMC 
It is recommended that every effort should be made for the DSMC to reach a unanimous decision.  If 
the DSMC cannot achieve this, a vote may be taken, and the majority position taken. Details of the 
vote should not be routinely included in the report to the TSC as these may inappropriately convey 
information about the state of the trial data. 
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It is important that the implications (e.g. ethical, statistical, practical, regulatory) for the trial be 
considered before any recommendation is made. 
The role of the Chair is to summarise discussions and encourage consensus; it may be best for the 
Chair to give their own opinion last. 
DSMC quorate for decision-making 
Effort should be made for all members to attend.  The meeting will be organised by the Condi 2 
Clinical Trials Unit who will try to ensure that a date is chosen to enable this. Members who cannot 
attend in person at face-to-face meetings can attend by teleconference.   
If, at short notice, any DSMC members cannot attend then the DSMC may still meet if the Chair and 
one other member is present and the absent member may provide input directly to the DSMC Chair.  
If the DSMC is considering recommending major action after such a meeting the DSMC Chair should 
talk with the absent member as soon after the meeting as possible to check they agree.  If they do 
not, a further meeting should be arranged with the full DSMC. 
1.1. Attendance at meetings 
If a member does not attend a meeting, it should be ensured that the member is available for the 
next meeting.  If a member does not attend a second meeting, they should be asked if they wish to 
remain part of the DSMC.  If a member does not attend a third meeting, they should be replaced. 
Reporting  
The DSMC will report its recommendations in writing to the TSC. This will be a letter sent to the trial 
TSC chair within 3 weeks of the DSMC meeting.  A copy of the letter should be sent to the chief 
investigator and Clinical Trials Unit for the Trial Master File and copied to TSC for the ERIC-PPCI trial. 
If the trial is to continue largely unchanged then it is often useful for the report from the DSMC to 
include a summary paragraph suitable for trial promotion purposes (see Annex 2). 
If the decision is made to recommend stopping the study the DSMC Chair will contact the TSC Chair 
immediately following the meeting to discuss this decision and the reasons why. The TSC together 
with the sponsor of the trial will make the final decision as to whether to stop the trial. 
Disagreement between the DSMC and the body to which it reports 
If the DSMC has serious problems or concerns with the TSC’s or Sponsor’s decision a meeting of 
these groups should be held. The information to be shown would depend upon the action proposed 
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and the DSMC’s concerns. Depending on the reason for the disagreement confidential data may 
have to be revealed to all those attending such a meeting.  
Post trial 
Publication of results  
The TSC will provide draft reports of the primary results of the trial to the DSMC for their 
consideration prior to submission for publication. The DSMC may provide comments to the TSC on 
the draft reports, and give advice about data interpretation.  
 
The information about the DSMC included in published trial reports 
DSMC members will be named and their affiliations listed in the main report, unless they explicitly 
request otherwise.  A brief summary of the timings and conclusions of DSMC meetings may be 
included if appropriate in the body of this paper. 
Any constraints on DSMC members divulging information about their 
deliberations after the trial has been published 
The DSMC may discuss issues from their involvement in the trial 6 months after the primary trial 
results have been published.  If a DSMC needs to discuss their involvement any earlier, permission is 
required from the TSC. 
Agreement 
This Charter is agreed by the following member of the DSMC: 
 
Name Signature and date 
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Figure 1: Trial flow diagram Condi 2 
Pre-hospital 
ECG telemedicin
Clinical symptoms recorded
In-hospital
Evaluation of tele-ECG and clinical symptoms
Pre-hospital 
Informed constent obtained
In-hospital
Randomisation 1 : 1
Control
Standard treatment
Perconditioning
Standard treatment
3 to 6 months follow up
Echocardiography
Quality of life 
Events
Cath. lab
Just prior to pPCI:  ECG and blood samples
pPCI procedure
Dept. of Cardiology
90 min. ECG
Echocardiography on day 1 to 3 post pPCI
Blood samples: 8, 24 and 48-72 hours post pPCI
1 year follow up
Quality of life 
Events
 
 
80 
 
Figure 2: Trial flow diagram ERIC-PPCI 
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Figure 3:  Flow of information for Condi 2 trial DSMC meetings 
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Table 1: Contact details of DSMC members and independent statistician 
Dr. Henning Kelbæk (DSMC Chair) (independent interventional cardiologist) 
Roskilde Hospital 
Køgevej 7-13,  
4000 Roskilde, Denmark 
Email: hkelbaek@dadlnet.dk 
Dr Héctor Bueno (independent interventional cardiologist) 
Director. Multidisciplinary Translational Cardiovascular Research (MTCR) Group 
Centro Nacional de Investigaciones Cardiovasculares (CNIC) 
Scientific Director 
Department of Cardiology 
Email: hector.bueno@cnic.es 
Jakob Hjort (Independent data manager) 
Palle Juul-Jensens Boulevard 82 
Bygning 2, stuen 
8200 Aarhus N 
Email: J.hjort@clin.au.dk 
Morten Madsen (Independent Statistician for Condi 2) 
Department of Epidemiology, Aarhus University Hospital, 
Olof Palmes Allé 43-45 
DK-8200 Aarhus N 
8200 Aarhus  
E-mail: Morten.madsen@clin.au.dk 
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Annex 1: Competing interests form 
Annex 2: Suggested report from DSMC to TSC where no recommendations are being made 
Annex 3:  Agreement on the non-disclosure of confidential information for the members of the data 
safety and monitoring committee (DSMC) 
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Introduction 
Title Effect of Remote Ischaemic Conditioning on clinical outcomes in ST-
segment elevation myocardial infarction patients undergoing Primary 
Percutaneous Coronary Intervention 
Acronym ERIC-PPCI 
Sponsor University College London 
NCT NCT02342522 
 
ERIC-PPCI is a randomised controlled trial to determine whether remote ischaemic conditioning (RIC) 
improves clinical outcomes after in patients with ST-segment elevation myocardial infarction 
undergoing Primary Percutaneous Coronary Intervention (PPCI).  Prof Derek Hausenloy (University 
College London, UK) is the Chief Investigator and the trial is managed by the Clinical Trials Unit at the 
London School of Hygiene & Tropical Medicine (LSHTM).  
The intervention is non-pharmacological. Patients are randomised to one of two groups: sham RIC 
(control) or RIC. The RIC treatment is applied on arrival at the hospital. Automated CellAegis 
autoRIC™ cuff devices will be used to deliver the RIC and sham RIC protocols. The active RIC 
treatment consists of four 5-minute inflations of the autoRIC™ cuff on the upper arm to 200mmHg, 
separated by 5-minute periods when the cuff will be deflated. For patients presenting with a systolic 
blood pressure (SBP) ≥175mmHg, a manual blood pressure cuff will be used and inflated to 25 
mmHg above systolic blood pressure. The sham RIC consists of a four 5-minute simulated inflations 
of the autoRIC™ cuff, separated by 5-minute periods when the cuff will be deflated.  
The reporting of final results from the ERIC-PPCI trial will be conducted in collaboration with Prof 
Hans Erik Bøtker (Aarhus University, Denmark), who is Chief Investigator of the CONDI2 trial, in order 
to maximise power to assess the impact of RIPC on clinical endpoints. In total 4300 STEMI patients 
will be recruited: 2000 STEMI patients will be randomised to ERIC-PPCI (Figure 1) and 2300 STEMI 
patients will be randomised to CONDI 2 (Figure 2). 
Primary endpoint 
The primary endpoint is occurrence of cardiac death and hospitalisation for heart failure (HHF) in 
STEMI patients 12 months after PPCI.  
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Major secondary endpoints 
9. Cardiac death and HHF at 30 days post PPCI.  
10. All-cause death at 30 days and 12 months. 
11. Repeat coronary revascularisation at 30 days and 12 months. 
12. Reinfarction at 30 days and 12 months. 
13. Stroke at 30 days and 12 months. 
14. TIMI flow post PPCI 
15. Quality of life at 6-8 weeks and 12 months (EuroQol EQ-5D-5L) 
Clinical outcome data will be collected at the telephone or outpatient follow-up at 6-8 weeks and 
one year post-PPCI. 
Outline of scope of charter  
The purpose of this document is to describe the roles and responsibilities of the independent DSMC 
for the ERIC-PPCI trial, including the timing of meetings, methods of providing information to and 
from the DSMC, frequency and format of meetings, statistical issues and relationships with other 
committees. 
The following documents were reviewed in preparation of this charter: 
 ERIC-PPCI trial protocol version 2, issued 24th Feb 2015 
 CONDI-2 trial protocol version 10.4, issued October 2015 
 Case report form (CRF) version 3, issued February 2016 
 London School of Hygiene and Tropical Medicine (LSHTM) Template charter for DMCs, 
issued 7th July 2015 
 DAMOCLES study group proposed charter for data monitoring committees data monitoring 
committees2 
Roles and responsibilities 
The DSMC role is to examine the data accumulated during progress of the ERIC-PPCI trial and ensure 
that the benefit/risk ratio remains acceptable for participating patients. It is the only committee 
which will have access to data broken down by treatment during the trial and on this basis, the 
primary responsibility of the DSMC is to review interim analyses of outcome data and to recommend 
                                                 
2 DAMOCLES Study Group (2005) A proposed charter for clinical trial data monitoring 
committees: helping them to do their job well. Lancet. 365: 711-22. 
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to the Trial Steering Committee (TSC) whether the trial needs to be changed or terminated based on 
these analyses. 
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More specifically, the duties of the DSMC will include: 
 monitoring evidence for treatment differences in the primary and secondary endpoints  
 monitoring evidence for treatment harm (e.g. SAEs, deaths) 
 assessing the impact and relevance of external evidence, particularly DSMC reports and 
recommendations from the ongoing CONDI 2 trial 
 deciding whether to recommend that the trial continues to recruit participants or whether 
recruitment should be terminated either for everyone or for some treatment groups and/or 
some participant subgroups  
 assessing data quality, including completeness  
 reviewing recruitment figures and monitor losses to follow-up 
 monitoring compliance with the protocol by participants and investigators 
 monitoring continuing appropriateness of patient information 
 monitoring compliance with previous DSMC recommendations 
 considering the ethical implications of any recommendations made by the DSMC 
DSMC input early in the trial 
All potential DSMC members should have sight of the trial protocol before finalising their agreement 
to join the committee. Before recruitment begins the trial will have undergone review by the 
sponsor, scrutiny by other trial committees and a research ethics committee. Therefore, if a 
potential DSMC member has major reservations about the trial (e.g. the protocol or the logistics) 
they should report these to the ERIC-PPCI Clinical Trials Unit and may decide not to accept the 
invitation to join. DSMC members should be independent and constructively critical of the ongoing 
trial, but also supportive of aims and methods of the trial. 
Initial DSMC meeting 
The DSMC will hold an initial meeting as early in the course of the trial as is reasonable practicable, 
to discuss the protocol, the trial, any analysis plan, future meetings, and to have the opportunity to 
clarify any aspects with the Trial Steering Committee. 
A DSMC statistical analysis plan, including a list of tables, will be provided prior to the initial meeting 
to familiarise the DSMC members with the intended content of the DSMC reports. The DSMC will 
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review the statistical analysis plan at the first meeting and confirm the content of the report to be 
provided at subsequent meetings. Alterations to the report can be made at subsequent meetings to 
reflect the requirements of the DSMC.  
DSMC composition 
All members of the DSMC have previous expertise in trials.  
The members of the DSMC for this trial are:  
Chair:  Prof Colin Berry - Chair (Professor of Cardiology and Imaging) 
Prof Tom Meade (Emeritus Professor of Epidemiology) 
Andrew Copas (Reader in Statistics) 
All DSMC members will maintain confidentiality, review available reports prior to meetings and 
contribute actively to developing the DSMC recommendations 
The DSMC Chair will communicate the written recommendations of the DSMC to the Chair of the 
TSC, determine whether additional meetings are required, and maintain documentation of 
communication between the DSMC and the TSC. 
The independent statistician supplying the DSMC, Jennifer Nicholas, will produce the confidential 
interim reports for the DSMC and distribute these at least one week prior to each meeting. She will 
also participate in DSMC meetings, guiding the DSMC through the report, and contributing to DSMC 
discussions. The statistician will also prepare and distribute meeting minutes to DSMC members as 
password protected files within one week after each meeting. 
The Chief Investigator, Prof Derek Hausenloy, and/or relevant members of the ERIC-PPCI Clinical 
Trials Unit will be invited to join the open session of the DSMC meeting to provide an update on trial 
progress. The ERIC-PPCI Clinical Trials Unit will provide a report on trial progress for discussion 
during the open session, for example recruitment, trial conduct etc.  
See Table 1 for full contact details of the DSMC and Independent Statistician. 
DSMC membership and their obligations 
Members of a DSMC are required to: 
(4) Confirm their agreement to take on the responsibilities of membership as outlined in this 
Charter  
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(5) Agree to maintain the confidentiality of the data provided and the deliberations of the 
Committee 
(6) Have no conflict of interest which will prejudice their role as a DSMC member 
By agreeing to adopt this Charter, all members confirm the above. 
Relationships 
Figure 3 details the organisation of the ERICC-PPCI trial and the reporting structure for the DSMC. 
The DSMC does not make decisions about the trial, but rather makes recommendations to the TSC. 
The DSMC for ERIC-PPCI and CONDI 2 will act as independent bodies. Therefore, the ERIC-PPCI DSMC 
will make their recommendations to the ERIC-PPCI TSC. This recommendation letter will be copied to 
the CONDI 2 TSC for their information. A reciprocal arrangement is place so the chair of the ERIC-
PPCI TSC receives a copy of recommendation letters of the CONDI 2 DSMC. 
The ERIC-PPCI DSMC members will be provided with copies of the CONDI 2 DSMC reports. 
Payments to DSMC members 
Members will be reimbursed for standard class travel for DSMC duties.  
The need for DSMC members to disclose information about any competing 
interests 
All competing interests should be disclosed prior to agreeing this Charter.  These are not restricted 
to financial matters – involvement in other trials or intellectual investment could be relevant.  
Although members may well be able to act objectively despite such connections, complete 
disclosure helps to enhance credibility (see Annex 1). 
DSMC members should not use interim results to inform trading in pharmaceutical shares, and 
careful consideration should be given to trading in stock of companies with competing products. 
DSMC organisation 
DSMC meetings will be conducted to review interim data. It is intended that the DSMC will meet to 
review interim results after 3-6 months of recruitment and then at least annually depending on the 
rate of accrual of data. 
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The DSMC will decide on the type of meeting required (face-to-face or teleconference). The ERIC-
PPCI Clinical Trials Unit will make arrangements accordingly. 
The format of the meetings will be as follows: 
3. Open session: Introduction and any “open” parts of the report 
4. Closed session: DSMC discussion of “closed” parts of the report  
Attendance at open and closed sessions 
In the open session all those attending the closed session are joined by the Chief Investigator and/or 
relevant members of the ERIC-PPCI Clinical Trials Unit. External experts may also be invited to the 
DSMC meetings at the request of the DSMC members. No unblinded data will be discussed during 
this session.  
In the closed session only members of the DSMC and others whom they specifically invite (e.g. 
Independent Statistician) will be present. The unblinded interim results will be discussed and the 
DSMC will decide on their recommendation to the Trial Steering Committee (TSC). 
DSMC closed session discussions will remain confidential and will not be communicated to the ERIC-
PPCI Clinical Trials Unit. 
Trial documentation and procedures to ensure confidentiality and 
proper communication 
Data for preparation of the interim report will be accessed by Jennifer Nicholas from the trial 
database using a unique username and password. In addition to this report, the DSMC will be 
provided with an update on trial progress from the ERIC-PPCI Clinical Trials Unit. These documents 
will be circulated at least 1 week in advance of the DSMC meeting.  
The interim reports on the CONDI 2 trial will be copied to the ERIC-PPCI DSMC members for 
consideration alongside the unblinded ERIC-PPCI report. Similarly, the interim reports from the ERIC-
PPCI trial will be copied to the CONDI 2 DSMC members for consideration alongside the CONDI 2 
report. 
Intended content of material to be available 
Open sessions: Accumulating information relating to recruitment and data quality (e.g. data 
return rates) will be presented.   
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Closed sessions: In addition to all the material available in the open session, the closed session 
material will include safety and efficacy data by treatment group. The unblinded CONDI 2 
interim reports from previous meetings of the CONDI 2 DSMC will also be available at this 
session. 
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The unblinded interim reports will contain details of: 
1. Patient recruitment 
2. Demographic and baseline characteristics 
3. Details of the RIC intervention 
4. Treatment times for PPCI (onset to balloon, door to balloon, 1st ECG to balloon times) 
5. IV medications given during PPCI 
6. Mortality and other safety endpoints 
7. Primary efficacy endpoint - cardiac death and HHF 
8. Unexpected Adverse and Serious Adverse Events 
9. Other endpoints identified by the DSMC  
 
The DSMC members should store the papers safely after each meeting so they may check the next 
report against them.  After the trial is reported, the DSMC members may destroy all interim reports.  
 
DSMC recommendations and decision making 
Possible recommendations could include:- 
 No action needed, trial continues as planned  
 Early stopping due, for example, to clear benefit or harm of a treatment, futility, or external 
evidence  
 Stopping recruitment within a subgroup 
 Extending recruitment (based on actual control arm response rates being different to 
predicted rather than on emerging differences) or extending follow-up 
 Sanctioning and/or proposing protocol changes 
Interim analyses and stopping rules 
It is not expected that the trial will be stopped for reasons of efficacy or futility based on observed 
treatment differences. A robust demonstration of efficacy is required to dispel scepticism that this 
simple intervention may be effective. Similarly, if there is no effect of the intervention then stopping 
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for futility will reduce the ability to demonstrate this. Therefore, the primary reason to recommend 
stopping the trial will be for safety reasons: 
 For the primary outcome, the DSMC will consider stopping if there is evidence of a 
difference in rate between the RIC and control group 
 For the main safety endpoints (e.g. mortality) the DSMC will consider stopping if there is 
evidence of greater event rate in the RIC group. 
As per the guidance of the DAMOCLES study group3, the DSMC will consider the strength of any 
formal statistical comparison alongside the internal consistency of results, consistency with external 
evidence and ability of the results to influence clinical practice. 
How decisions or recommendations will be reached within the DSMC 
It is recommended that every effort should be made for the DSMC to reach a unanimous decision.  If 
the DSMC cannot achieve this, a vote may be taken, and the majority position taken. Details of the 
vote should not be routinely included in the report to the TSC as these may inappropriately convey 
information about the state of the trial data. 
It is important that the implications (e.g. ethical, statistical, practical, regulatory) for the trial be 
considered before any recommendation is made. 
The role of the Chair is to summarise discussions and encourage consensus; it may be best for the 
Chair to give their own opinion last. 
DSMC quorate for decision-making 
Effort should be made for all members to attend.  The meeting will be organised by the ERIC-PPCI 
Clinical Trials Unit who will try to ensure that a date is chosen to enable this. Members who cannot 
attend in person at face-to-face meetings can attend by teleconference.   
If, at short notice, any DSMC members cannot attend then the DSMC may still meet if the Chair and 
one other member is present and the absent member may provide input directly to the DSMC Chair.  
If the DSMC is considering recommending major action after such a meeting the DSMC Chair should 
talk with the absent member as soon after the meeting as possible to check they agree.  If they do 
not, a further meeting should be arranged with the full DSMC. 
                                                 
3 DAMOCLES Study Group (2005) A proposed charter for clinical trial data monitoring 
committees: helping them to do their job well. Lancet. 365: 711-22. 
95 
 
1.2. Attendance at meetings 
If a member does not attend a meeting, it should be ensured that the member is available for the 
next meeting.  If a member does not attend a second meeting, they should be asked if they wish to 
remain part of the DSMC.  If a member does not attend a third meeting, they should be replaced. 
Reporting  
The DSMC will report its recommendations in writing to the TSC. This will be a letter sent to the trial 
TSC chair within 3 weeks of the DSMC meeting.  A copy of the letter should be sent to the chief 
investigator and Clinical Trials Unit for the Trial Master File and copied to the trial TSC chair of the 
CONDI 2 trial. If the trial is to continue largely unchanged then it is often useful for the report from 
the DSMC to include a summary paragraph suitable for trial promotion purposes (see Annex 2). 
If the decision is made to recommend stopping the study the DSMC Chair will contact the TSC Chair 
immediately following the meeting to discuss this decision and the reasons why. The TSC together 
with the sponsor of the trial will make the final decision as to whether to stop the trial. 
Disagreement between the DSMC and the body to which it reports 
If the DSMC has serious problems or concerns with the TSC’s or Sponsor’s decision a meeting of 
these groups should be held. The information to be shown would depend upon the action proposed 
and the DSMC’s concerns. Depending on the reason for the disagreement confidential data may 
have to be revealed to all those attending such a meeting.  
Post trial 
Publication of results  
The TSC will provide draft reports of the primary results of the trial to the DSMC for their 
consideration prior to submission for publication. The DSMC may provide comments to the TSC on 
the draft reports, and give advice about data interpretation.   
The information about the DSMC included in published trial reports 
DSMC members will be named and their affiliations listed in the main report, unless they explicitly 
request otherwise.  A brief summary of the timings and conclusions of DSMC meetings may be 
included if appropriate in the body of this paper. 
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Any constraints on DSMC members divulging information about their 
deliberations after the trial has been published 
The DSMC may discuss issues from their involvement in the trial 6 months after the primary trial 
results have been published.  If a DSMC needs to discuss their involvement any earlier, permission is 
required from the TSC. 
Agreement 
This Charter is agreed by the following member of the DSMC: 
 
Name Signature and date 
   
 
 
 
Figures and appendices 
Figure 1: Trial flow diagram ERIC-PPCI 
Figure 2: Trial flow diagram CONDI 2 
Figure 3: Flow of information for ERIC-PPCI trial DSMC meetings 
 
Table 1: Contact details for DSMC members and independent statistician 
 
Annex 1: Competing interest form 
Annex 2: Suggested letter from DSMC to TSC where no recommendations are being made. 
Annex 3: Confidentiality Agreement 
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Figure 1: Trial flow diagram ERIC-PPCI 
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Figure 2: Trial flow diagram CONDI 2 
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Figure 3:  Flow of information for ERIC-PPCI trial DSMC meetings 
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Table 1: Contact details of DSMC members and independent statistician 
Professor Colin Berry (DSMC Chair) 
BHF Glasgow Cardiovascular Research Centre 
University of Glasgow, G12 8TA 
Email: Colin.Berry@glasgow.ac.uk 
Professor Tom Meade 
Dept. Non-Communicable Disease Epidemiology 
London School of Hygiene & Tropical Medicine 
Keppel Street 
London  
WC1E 7HT 
Tel: 020 7927 2182 
Email: Tom.Meade@lshtm.ac.uk 
Dr Andrew Copas 
UCL Research Department of Infection and Population Health  
The Mortimer Market Centre 
Capper St 
London  
WC1E 6JB 
Tel: 020 3108 2062 
Email: a.copas@ucl.ac.uk 
Dr Jennifer Nicholas (Independent Statistician for ERIC-PPCI) 
Lecturer in Medical Statistics 
Department of Medical Statistics, 
London School of Hygiene and Tropical Medicine, 
Keppel Street, 
London 
WC1E 7HT  
Tel: 020 958 8119 
E-mail: jennifer.nicholas@lshtm.ac.uk 
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Annex 1: Competing interests form 
Annex 2: Suggested report from DSMC to TSC where no recommendations are being made 
Annex 3:  Agreement on the non-disclosure of confidential information for the members of the data 
safety and monitoring committee (DSMC) 
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Data handling- ERIC-PPCI 
 
ERIC-PPCI used a bespoke database built by Sealed Envelope, Inc (London, UK) and hosted 
by Rackspace. The database was compliant with NHS and UK data handling requirements. 
Patient data was entered directly to the database by hospital research staff using a password 
protected online portal. Data was reviewed and queried by LSHTM Staff to ensure accuracy. 
Patient identifiable information was stored only with patient consent or with the approval of 
the UK Confidentiality Advisory Group.  
 
 
 
 
Data handling- CONDI-2 
 
Condi-2 used the 24-7 accessible web-based clinical trial support system TrialPartner 
(Aarhus, DK). The database is compliant with all Danish/EU data handling requirements. 
Personal logons permitted patient data to be entered directly to the database by hospital 
research staff at the recruiting sites. Data were reviewed and queried by the staff at the 
coordination centre at Aarhus University Hospital to ensure completeness and accuracy. 
Patient identifiable information was stored only with patient consent. 
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